This web only provides the extract of this article. If you want to read the figures and tables, please reference the PDF full text on Blackwell Synergy. Thank you.
- Review -
Effects of phosphodiesterase 5 inhibitors on sperm parameters and
fertilizing capacity
F. Dimitriadis1, D. Giannakis1, N. Pardalidis1, K. Zikopoulos1,
E. Paraskevaidis1, N. Giotitsas1, V. Kalaboki1, P. Tsounapi1,
D. Baltogiannis1, I. Georgiou1, M. Saito2, T. Watanabe2,
I. Miyagawa2, N. Sofikitis1, 2
1Laboratory of Molecular Urology and Genetics of Human Reproduction, Department of Urology Ioannina University
School of Medicine, Ioannina 45110, Greece
2Department of Urology Tottori University School of Medicine, Yonago 683, Japan
Abstract
The aim of this review study is to elucidate the effects that phosphodiesterase 5 (PDE5) inhibitors exert on
spermatozoa motility, capacitation process and on their ability to fertilize the oocyte. Second messenger systems
such as the cAMP/adenylate cyclase (AC) system and the cGMP/guanylate cyclase (GC) system appear to regulate
sperm functions. Increased levels of intracytosolic cAMP result in an enhancement of sperm motility and viability.
The stimulation of GC by low doses of nitric oxide (NO) leads to an improvement or maintenance of sperm motility,
whereas higher concentrations have an adverse effect on sperm parameters. Several
in vivo and in vitro studies have been carried out in order to examine whether PDE5 inhibitors affect positively or negatively sperm parameters and
sperm fertilizing capacity. The results of these studies are controversial. Some of these studies demonstrate no
significant effects of PDE5 inhibitors on the motility, viability, and morphology of spermatozoa collected from men
that have been treated with PDE5 inhibitors. On the other hand, several studies demonstrate a positive effect of PDE5
inhibitors on sperm motility both in vivo and
in vitro. In vitro studies of sildenafil citrate demonstrate a stimulatory
effect on sperm motility with an increase in intracellular cAMP suggesting an inhibitory action of sildenafil citrate on
a PDE isoform other than the PDE5. On the other hand, tadalafil's actions appear to be associated with the inhibitory
effect of this compound on PDE11. In vivo studies in men treated with vardenafil in a daily basis demonstrated a
significantly larger total number of spermatozoa per ejaculate, quantitative sperm motility, and qualitative sperm
motility; it has been suggested that vardenafil administration enhances the secretory function of the prostate and
subsequently increases the qualitative and quantitative motility of
spermatozoa. The effect that PDE5 inhibitors exert on
sperm parameters may lead to the improvement of the outcome of assisted reproductive technology (ART) programs.
In the future PDE5 inhibitors might serve as adjunct therapeutical agents for the alleviation of male
infertility. (Asian J Androl 2008 Jan; 10: 115_133)
Keywords: sperm fertilizing capacity; phosphodiesterase 5 inhibitors; spermatozoa; testis; male infertility
Correspondence to: Prof. Nikolaos Sofikitis, Department of Urology, Ioannina University School of Medicine, Ioannina 45110, Greece.
Tel: +30-6944-3634-28 Fax: +30-2651-0970-69
E-mail: akrosnin@hotmail.com
DOI: 10.1111/j.1745-7262.2008.00373.x
1 Second messenger systems
A second messenger system is a group of intracellular independent but interrelated elements; within this group of
molecules an intracellular signal is generated in response to an intercellular first messenger molecule. Hormones or
neurotransmitters can serve as primary messengers. Second messenger systems are thought to be intermediate
signals in cellular processes such as metabolism, secretion, or cell growth. The primary signal molecule does not
enter the cell but utilizes a cascade of molecular events in order to induce a cellular response. Hormones utilize second
messenger systems and interestingly it has been shown that a single hormone can utilize more than one second
messengers.
There are four major classes of second messenger systems: a) the tyrosine kinase system, b) the
inositol-1,4,5-trisphosphate (IP3)/diacylglycerol (DAG) system, c) calcium ions
(Ca2+), and d) cyclic nucleotides (e.g.,
3',5'-cyclic adenosine monophosphate [cAMP] and
3',5'-cyclic guanosine monophosphate [cGMP]). A second messenger
system comprises of several elements including the first
messenger, the primary messenger's receptor, a second
receptor called G protein that interacts with the primary
messenger's receptor, an enzyme triggered into action
by the interacting pair of receptors, and a second
messenger molecule generated by this enzyme. The
intracellular signal generated in response to the first
messenger is amplified into the cell.
1.1 Tyrosine kinase second messenger system
Insulin is an example of a hormone whose receptor
is a tyrosine kinase. This hormone binds to domains
exposed on the cell's surface resulting in a
conformational change that activates the kinase domains located in
the cytoplasmic regions of the receptor. In several cases,
the receptor phosphorylates itself as part of the kinase
activation process. The activated receptor
phosphorylates a variety of intracellular targets; most of them are
enzymes that become activated or are inactivated upon
phosphorylation.
1.2 DAG/protein kinase C (PKC) second messenger
system
DAG/PKC second messenger system is the second messenger system for primary messengers such as
thyroid-stimulating hormone (TSH), angiotensin, or
neurotransmitters. The above primary messengers bind to G
protein-coupled receptors and subsequently the alpha
subunit of the G protein activates an intracellular enzyme
called phospholipase C. This enzyme hydrolyzes the
phosphatidylinositol-4,5-bisphosphate (PIP2) which is
found in the inner layer of the plasma membrane. The
products of the hydrolysis are DAG and IP3. After the
hydrolysis, DAG remains at the inner layer of the plasma
membrane, due to its hydrophobic properties, and
recruits PKC (a calcium dependent kinase). The
phosphorylation of other proteins by PKC causes several
intracellular changes. Calcium ions are required for PKC to be
activated; the other second messenger, IP3, renders
calcium ions available for PKC. IP3 is a soluble molecule
that diffuses through the cytosol and binds to receptors
on the smooth endoplasmic reticulum causing the release
of Ca2+ into the cytosol. The latter rise of intracellular
calcium triggers the cellular response (Figure 1).
1.3 Ca2+
Ca2+ is the most widely involved and important
intracellular messenger. As a response to several primary
signals the subsequently elevated concentration of
Ca2+ triggers many types of events such as muscle contraction,
release of neurotransmitters at synapses, secretion of
hormones like insulin, activation of T cells and B cells
(when they bind antigen with their antigen receptors),
and apoptosis.
1.4. Adenylate cyclase (AC)/cAMP second messenger
system
cAMP is a nucleotide generated from ATP through
the action of the enzyme adenylate cyclase. A variety of
hormones can trigger an increase or decrease of the
intracellular concentration of cAMP. The elevated
concentrations of cAMP can activate a cAMP-dependent
protein kinase called protein kinase A (PKA). This
protein is at a catalytically-inactive state but becomes active
when it binds cAMP.
Cyclic AMP was discovered in 1958 by Rall and Sutherland [1] and since then many biochemical actions
were attributed to this molecule such as stimulation of
glycogen degradation, gluconeogenesis, lipid degradation,
steroid synthesis, inhibition of glycogen synthesis, amino
acid uptake, and regulation of ion transport as well as
regulation of transcription. It is formed by the action of
AC on ATP-Mg2+ complex. Free
Mg2+ is a necessary cofactor. Moreover two other proteins are involved in
the cAMP-dependent signal transduction mechanisms:
(1) a hormone receptor, and (2) a G-protein, a
heterodimer. Receptors which associate with G-proteins of the
Gs-type stimulate AC and receptors which associate with
G-proteins of the Gi-type inhibit AC. The cAMP that is
formed activates "cAMP-dependent protein kinase", also
called PKA, which is involved in several metabolic
pathways acting by phosphorylating other proteins (enzymes,
transporters, etc.).
Hormones such as adrenaline, glucagons, and
luteinizing hormone (LH) exert their effects using cAMP as a
second messenger. The above hormones bind to their
receptors in the membrane of target cells interacting
subsequently with a set of G proteins. This interaction
triggers AC which initiates the conversion of ATP to cyclic
AMP with an overall result an elevated intracellular
concentration of cAMP. The increased levels of cAMP
activate PKA as mentioned above. The activated PKA
promotes a cascade of events into the cell, adding
phosphates to other enzymes, changing their structure and
thereby modulating their catalytic activity.
1.5. Guanylate cyclase (GC)/cGMP second messenger
system
The description of the cyclic nucleotides cAMP and
cGMP led to the first formulation of the second
messenger concept. Very similar to the cAMP, cGMP is
another important second messenger. It was described as
a biological product in 1963 but the regulation of its
synthesis has remained obscure until very recently. Its
concentration in the tissues is relatively low. This was the
reason cGMP was not considered as a potential second
messenger for several years. Subsequently it has
become clear that cGMP plays a pivotal role in controlling
a wide variety of biological processes such as retinal
phototransduction, intestinal secretion, smooth muscle
relaxation, platelet activation, and neurotransmission [2].
Cyclic GMP is generated from GTP via a reaction
catalyzed by the ubiquitous enzymes GC which are expressed
in both soluble (sGC) and particulate, membrane-bound
(mGC) isoforms. These isoforms co-exist in most cells
in different concentrations depending on the type and
the physiological state of the tissue [3]. The mGC is a
cell surface receptor enzyme that contains an
extracellular receptor domain and an intracellular catalytic domain
separated by a single transmembrane domain [4].
Several subclasses of mGC have been identified so
far in vertebrates. They are homodimeric glycoproteins
[5, 6], and probably are associated with the plasma
membrane, the endoplasmic reticulum, the Golgi bodies,
and the nuclear membrane [3]. The various subclasses
of mGC represent the receptors for three structurally
similar peptides (atrial natriuretic peptide, B-type
natriuretic peptide, and C-type natriuretic peptide) [7, 8].
Other mGC subclasses bind the heat-stable enterotoxin
of Escherichia coli [5, 9].
The soluble isoform of guanylate cyclase sGC includes a group of heterodimeric hemoproteins composed
of α- and β-subunits [6]. It contains also a prosthetic
heme group on each heterodimer [4] which can bind diffusible gases such as nitric oxide (NO) and carbon
monoxide [5]. The enzyme's catalytic activity is
enhanced after binding from a 5-fold level (with carbon
monoxide) to a 400-fold (with NO) [4].
2 cAMP, cGMP and regulation of the erectile
function
Penile erection requires an increase in blood flow to
the penis as a consequence of cavernous smooth muscle
relaxation and restriction of venous outflow from the
corpus cavernosum [10]. This process is mediated by
parasympathetic cholinergic pregangliotic neurons
residing within the sacral spinal cord (S2-4). The cavernous
nerves arise from the pelvic nerves that exit the above
mentioned S2-4 region of the sacral spinal cord and
provide the autonomic input to the penis. These nerves
release various neurotransmitters including nitric oxide,
acetylcholine (Ach), and vasoactive intestinal peptide
(VIP) that are capable of relaxing the cavernous smooth
muscle [10]. The release of NO is thought to activate
cytosolic GC enzymes increasing the intracellular cGMP
level and reducing the cytosolic Ca2+ content. Moreover
NO appears to reduce norepinephrine release from
noradrenergic nerves [11]. The AC/cAMP second
messenger system is also implicated in the penile erection. VIP
acts through the AC pathway to trigger an increase in
intracellular cAMP level [12]. A rise in intracellular cAMP
results in a fall in cytosolic Ca2+ in cavernous smooth
muscle which causes relaxation of cavernous smooth
muscle.
3 Regulation of sperm function by second
messenger systems
3.1 Sperm function and AC/cAMP second messenger
system
Cyclic AMP appears to be involved in the signaling
pathways that regulate sperm motility [13, 14] as well as
sperm capacitation [15]. In fact increased levels of
intracytosolic cAMP have been demonstrated to enhance
sperm motility and viability [16, 17] by a) increasing the
rate of glycolysis and fructolysis and b) enhancing the
oxidation of lactate or pyruvate to CO2 [18].
Yanagimachi [19] has reported that the asymmetrical,
high amplitude beats of the sperm flagellum (referred to
as "hyperactivated motility") and the capacitation
process are dependent on the intracellular cAMP levels. These
findings are consistent with those of MacLeod et
al. [20] who demonstrated that the majority of the
cAMP-dependent protein kinases in the rat spermatozoa are
located within the flagellum. Furthermore, cAMP seems
to play an important role in the regulation of the
capacitation process and the acrosome reaction [21_23].
3.2 Sperm function and GC/cGMP second messenger
system
Nitric oxide, this ubiquitous, short-lived, mediator of
cell-to-cell interaction is synthesized by nitric oxide
synthases (NOS) in many mammalian cell types [24] in
response to a large number of stimuli. Spermatozoa
themselves express an NOS activity and are able to
synthesize nitric oxide [17, 25_28]. Specific chemical stimuli
can enhance spermatozoal NO production [26, 28]. The
presence of endothelial and neuronal NOS isoforms in
human spermatozoa has been demonstrated in several
studies [17, 25, 27, 28]. NO is known to affect sperm
motility and viability in a concentration-related fashion.
At low doses nitric oxide is found to improve or maintain
sperm motility probably through the stimulation of cGMP
production [17, 29], whereas, at higher concentrations
of nitric oxide, sperm motility and viability are adversely
affected, most likely due to nitric oxide ability to serve as
a free radical and cause direct oxidative damage in the
spermatozoal membrane [30].
GC-activating substances (in particular atrial
natriuretic peptide and nitric oxide) strongly affect positively
sperm motility, capacitation, and acrosomal reactivity.
These substances stimulate sperm metabolism and
promote the sperm capacity to approach the oocyte,
interact with it, and finally fertilize it [31]. Interesting studies
have indicated that the sperm acrosome reaction rate is
greatly influenced by cGMP synthesis [31]. A complex
cross-talk phenomenon between the cAMP- and the
cGMP-generating systems regulating the sperm function occurs in human spermatozoa [32].
Spermatogenesis, and sperm-egg interaction appears to be positively
affected by sperm GC activation, whereas recent experimental observations indicate that excessive amounts
of certain GC activators might exert opposite,
antireproductive effects through an increase in the oxidative stress
and the lipid peroxidation on sperm membranes [30, 33,
34]. In general important final events of the fertilization
process (i.e., acrosomal reaction) are regulated by
interactions between second messenger systems. Sofikitis
et al. [32] have shown an interaction between the
AC/cAMP second messenger system and phorboldiester/PKC
second messenger system in the regulation of sperm
acrosome reaction process.
4 Phosphodiesterases (PDEs): general
considerations
The cyclic nucleotide PDEs play the dominant role
in the degradation of the cAMP and cGMP. The PDEs
function in conjunction with AC and GC to regulate the
amplitude and duration of intracellular signaling
mechanisms (mediated via cAMP and cGMP, respectively).
Sequence analyses suggest that there are at least 11
different families of mammalian PDEs. Most of the
families include more than one gene product. In addition,
many of these genes can be alternatively spliced in a
tissue specific manner. The overall result is the generation
of different mRNAs and proteins with altered regulatory
properties or subcellular localization.
PDEs are named to precisely identify the isoenzyme
being referenced. Thus the first two letters of PDEs
describe the species of origin followed by PDE and the
arabic numeral of the gene family. The next letter
represents the individual gene within the family, and the last
arabic numeral identifies the transcript variant. For
example, HSPDE1A1 refers to the human PDE1 family,
gene A, transcript variant 1. Each PDE family displays
different a) substrate specifity, b) kinetic properties, c)
allosteric regulation, and d) interaction with specific
inhibitors. Thus, some PDEs hydrolyze only cAMP (PDE4, PDE7 and PDE8), some PDEs hydrolyze only
cGMP (PDE5, PDE6 and PDE9), while other PDEs demonstrate mixed specificities and hydrolyze both cAMP
and cGMP (PDE1, PDE2, PDE3, PDE10 and PDE11). Therefore, the expression profile of PDEs within a given
cell may determine the type of cyclic nucleotide
hydrolyzed in that cell or subcellular region. The distinct
cellular localization and biophysical characteristics of the
various PDEs suggest that each PDE transcript variant
plays distinct roles in specific physiological processes.
PDE1 family for example involves three gene products
(PDE1A, PDE1B, and PDE1C) [35] which are
activated by the binding of calmodulin in the presence of
calcium [36] leading to an increase in hydrolysis of both
cAMP and cGMP. More specifically, PDE1A and PDE1B
enzymes selectively hydrolyze cGMP while the PDE1C
variant hydrolyzes both cAMP and cGMP with high
affinity [37, 38]. Northern blot analysis and
in situ hybridization revealed that PDE1 is expressed in heart, brain,
skeletal muscle, smooth muscle, as well as in other
peripheral tissues [39, 40]. Direct catalytic site inhibitors
such as vinpocetine and 8-methoxy-1-methyl-3-isobutylxanthine (IBMX) inhibit PDE1 activity. However the
latter inhibitors demonstrate limited inter-PDE family
selectivity [38, 41]. Vinpocetine is actually used in many
regions of Europe, Japan and Mexico as pharmaceutical
treatments for cerebrovascular and cognitive disorders
or as a dietary supplement in the United States. No side
effects attributable to this medicine have been observed
but the doses of these enzymes required for the
pharmacological effect are high.
The cGMP-stimulated PDE2A type hydrolyzes both cAMP and cGMP, although it has a higher affinity for
cGMP than for cAMP [42]. There is a single PDE2 gene
which encodes three PDE2 splice variants [43, 44].
Human PDE2A is expressed in brain, adrenal cortex [45],
and to a lesser extend in heart, liver, skeletal muscle,
kidney and pancreas [44]. It has been shown to play a
role in regulating aldosterone production in adrenal
glomerulosa cells through regulation of cAMP and cGMP
intracellular levels. Moreover PDE2A seems to play a
role in regulating cGMP-mediated effects in blood
platelets [46], cardiomyocyte and vascular endothelial cells
[47]. Finally in a recent study it has been demonstrated
that the inhibition of this PDE type by a novel PDE
inhibitor named Bay-60-7550 seems to improve memory
functions by enhancing neuronal plasticity [48].
Furthermore PDE2 is inhibited by
erythro-9-(2-hydroxy-3-nonyl) adenine (EHNA) a potent adenosine deaminase
inhibitor [49].
The PDE3 family members allow cGMP to potentiate a cAMP signal in cells where PDE3 family members
are expressed. This family is composed of two genes:
PDE3A and PDE3B. PDE3A is involved in the
regulation of platelet aggregation while
PDE3B mediates the insulin regulation of lipolysis in adipocytes. In addition
PDE3B mediates leptin inhibition of insulin secretion in
pancreatic beta cells [50]. Furthermore,
PDE3B mRNA concentration is highest in adipocytes, hepatocytes, brain,
renal collecting duct epithelium, and developing
spermatocytes [51]. Some tissues may express both
PDE3A and PDE3B but the levels of
PDE3A are usually higher [52, 53]. PDE3 variants are activated by PKA or PKB
phosphorylation. Consensus sites of phosphorylation for
each kinase are located between NHR1 and NHR2 in both
PDE3A and PDE3B [53]. On the other hand
PDE3A and PDE3B are directly inhibited by cGMP-mediated
competition for cAMP binding to the active site. This was
the reason why PDE3 was also referred to as cGMP-inhibited cAMP PDE in the earlier literature. PDE3
enzymes were therapeutic targets of great interest in
cardiovascular system [53_55]. A few selective inhibitors
of PDE3 family exist, including milrinone, amrinone,
cilostamide, and cilostazol.
PDE4 family hydrolyses exclusively cAMP. It has
been shown that there are four isoforms (A, B, C and D)
each coded by a separate gene in both rodents [56] and
the human [57]. Each isoform is characterized by a
unique N-terminal region. These variants have closely
related kinetic properties and requirements for ions.
Functional PDE4 isoforms can be divided into three
major categories: long, short and super-short [58]. These
isoforms are expressed in almost all cell types except
blood platelets [37]. PKA-dependent phosphorylation
selectively activates many long PDE4 isoforms [59, 60].
It is interesting that PDE4 selective inhibitors
demonstrate in animal models potent anti-inflammatory actions.
Indeed, there is currently much interest in employing
selective PDE4 inhibitors for the treatment of asthma,
chronic obstructive pulmonary disease [61], rheumatoid
arthritis and cancer. Moreover these inhibitors can also
exert antidepressant actions [62_64].
PDE5 specifically hydrolyses cGMP to 5' GMP. This
PDE family consists of a single PDE5 gene (Figure 2).
Furthermore, the existence of three alternatively spliced
PDE5 isoforms (PDE5A1, 2 and 3) has been demonstrated.
These isoforms differ only in the 5' ends of their
corresponding mRNAs and in the corresponding N-termini of
sproteins [65, 66]. PDE5A1 and PDE5A2 are co-expressed in a variety of tissues. However, PDE5A3
appears to be expressed in smooth muscle cells only [67,
68]. The success of PDE5 selective inhibitors in the
treatment of the erectile dysfunction (ED) has increased
the interest to investigate the effects of inhibiting PDE5
in vascular, thrombotic, or pulmonary disorders [69].
Cyclic GMP PDE in retinal photoreceptors, classified
as PDE6, is a key enzyme in the vertebrate
phototransduction. Indeed phototransduction in cones and rodes is
mediated primarily through the action of three proteins:
the receptor (i.e. rhodopsin), a G-protein (i.e. transducin),
and the 3',5' cyclic nucleotide PDE6. The two PDE6
isoforms are actually the only PDE family enzymes [69,
70] in the photoreceptor outer segments. PDE6 is a
heterotrimeric enzyme functioning to lower cytoplasmic
cGMP levels in response to light activation of the receptor
rhodopsin [71_73]. It is composed of two homologous
catalytic subunits (Pα, β) and two identical inhibitory
subunits Pγ. PDE6 activity is inhibited by selective PDE
inhibitors such as zaprinast [74], sildenafil, tadalafil [75],
and vardenafil [76].
The PDE7 family includes cAMP-specific PDEs. Two
genes of this family have been identified:
PDE7A and PDE7B. PDE7A has three isoforms, generated by
alternate splicing, which are found mainly in a) the T cells
and the brain (PDE7A1), b) the muscle cells (PDE7A2),
and c) the activated T cells (PDE7A3) [77_79].
PDE7B has approximately 70% homology to PDE7A [80, 81].
PDE7 family plays a pivotal role in the regulation of
human T cell functions including cytokine production,
proliferation, and expression of activation markers. Thus
selective PDE7 inhibitors may have role in the treatment
of T cell-mediated diseases and disorders of the airways
[82]. However, currently there is an absence of a
selective PDE7 inhibitor [83]. Promising results are yielded
from novel PDE7 inhibitors like iminothiadiazoles [84]
which have been proposed on patent literature.
The PDE8 family contains high-affinity cAMP-specific IBMX-insensitive PDEs. They are composed of
two isoforms PDE8A and PDE8B and so far, they have
been identified in the human and mouse [85_87]. While
PDE8A1 is widely distributed in various tissues, such as
the testis, spleen, colon, small intestine, ovary, placenta,
and kidney [87]. PDE8B is found only in the human
thyroid gland.
PDE9 is a cGMP-specific PDE. The encoded protein of this gene plays a role in signal transduction by
regulating the intracellular concentration of cGMP.
Multiple-tissue Northern blot analyses have revealed high
levels of PDE9 in brain, heart, placenta, adult and fetal
kidney, spleen, prostate, and colon [88]. Moreover
PDE9A was mapped to human chromosomal region 21q22.3, a critical region for two genetic diseases: the
nonsyndromic hereditary deafness [89, 90], and the
bipolar affective disorder [91_93]. The above
observations may suggest a role of disorders in the regulation of
the expression of this enzyme in the development of these
diseases. The only PDE inhibitor that seems to
inactivate PDE9A is zaprinast [94]. The presence of only one
inhibitor is a barrier for major research efforts that focus
to investigate the role of PDE in the above two
pathophysiologies.
PDE10A has been categorized as cGMP-binding PDE.
It is expressed in the putamen and caudate nucleus
regions. The latter regions have dopamine receptors and
are related to juvenile Parkinsonism. Therefore a genetic
relationship between the PDE10A gene and this disease
cannot be excluded [95]. PDE10A is moderately
inhibited by IBMX a non-specific PDE inhibitor.
By screening a human skeletal muscle cDNA
library, Fawcett et al. [96] cloned a human PDE gene family
member. The authors denoted the latter PDE genes as
PDE11A (in accordance with the standardized nomenclature [97]). This partially purified-recombinant human
PDE11A1 has the ability to hydrolyse both cAMP and
cGMP [96]. It is sensitive to the non-selective inhibitor
IBMX, to zaprinast, and to pyridamole. In adittion
pyridamole inhibits PDE11A with potency approximately
equal to that for PDE5 or PDE6. PDE11A is expressed
as at least three distinct major transcripts. The latter
transcripts can be found at highest levels in skeletal
muscles and the human prostate [96]. Northern blot
analysis revealed wider expression of these transcripts
in kidney liver, pituitary and salivary glands, and testis.
The differential tissue distribution of PDEs makes
them attractive targets for the development of
cell-specific drugs. Indeed selective inhibitors of PDEs have
been widely studied as cardiotonics, vasodilators,
smooth-muscle relaxants, antidepressants, antithrombotics,
antiasthmatics, and agents for improving cognitive
functions such as learning and memory [98_105]. So far a
limited number of PDE inhibitors are commercially available. However these compounds display only
partial selectivity for specific PDE isoforms. Selective
inhibitors for many PDE families are still not available, in
particular for the PDE isoforms 8, 9, and 10.
The evaluation and the action of PDE inhibitors
in vivo or in vitro is limited by a number of factors
including the specific cell permeability, the uncertainty of the
actual intracellular concentration of inhibitor, and the
profile and subcellular localization of the PDEs in the
specific cell type being studied. Several times there is a
disparity between the cellular effect of an inhibitor in
vitro and the cellular effect of the same inhibitor
in vivo. This is the result of the complexity of the
in vivo conditions compared with a purified enzyme assay
in vitro experiments. For example, trequinsin has been tested
successfully in vivo as a PDE2 inhibitor [106]. However,
in vitro this inhibitor is actually much more potent for
the inhibition of PDE3 [107, 108].
5 PDEs isoforms in the male genital system
Recently, scientists focused their efforts on the
understanding of the regulatory mechanisms responsible
for the contraction and relaxation of the male genital ducts.
These studies may clarify the mechanisms responsible
for the transport of spermatozoa from the seminiferous
tubuli through the remaining male genital duct. Although
there are still many issues to be elucidated, it has been
demonstrated that the messenger molecule cGMP is
crucial for the regulation of contractility of seminiferous
tubules in man [109, 110], the human testicular capsule
[111], and the epididymal ducts [112]. In addition,
contractility studies and analyses of GC-B-knockouts mice
[113] have demonstrated that cGMP-dependent relaxation mechanisms appear to be of paramount importance
on the regulation of transport and maturation of
spermatozoa in the epididymis.
Detailed analyses of tissue- and cell type-specific
distribution of PDE gene families, however, in the testis
and epididymis are still lacking. The literature reveals
data on PDE expression in testis restricted predominantly
to cAMP-hydrolyzing PDEs such as PDE1C, PDE4A, PDE4C, PDE7B, and PDE8A and provides also useful
information about PDEs localization in male germ cells
and spermatozoa [114]. Transcripts of the PDE10 were
found in the human testis [115].
cGMP-hydrolyzing-PDE5 was recently localized in peritubular myoid cells
of the rat [116]. Moreover the potential functions of
PDE11 in the regulation of spermatogenesis process and
sperm function has been an issue of major clinical
importance since PDE11 serves as a substrate for the
commonly used substance tadalafil [117]. Regulation of
epididymal duct contractility by PDE3 has been suggested [112].
6 PDE in human spermatozoa
NOS [17] and PDE have also been found in male gametes since 1971 [118]. In fact there is evidence for
the presence of more than one isoforms of PDEs in spermatozoa. Measurements of spermatozoal PDE
activity in the presence of inhibitors for PDE1 or PDE4
confirmed the presence of PDE1 and PDE4 in human spermatozoa [22]. In the same study the auhtors
concluded that the PDE4 is distributed in sperm flagella,
midpiece, and cytoskeletal structure. In contrast, PDE1
activity is more evenly distributed in all the above three
sperm regions. Immunocytochemical data has suggested
that PDE4 is localized mainly in the sperm midpiece while
the PDE1 is found largely in the sperm head [22].
In a recent study Lefièvre et al. [119] identified in
ejaculated human spermatozoa two PDE isoforms: PDE1A and PDE3A. Their activities were detected in
both the soluble and particulate fractions. The authors
also reported that PDE1A is located in the equatorial
region of sperm head, midpiece and principal piece of the
tail while PDE3A is located in the postacrosomal region
of the sperm head. The latter finding may suggest a role
of PDE3A in the regulation of sperm membrane
alterations which are important for the sperm capacitation
process and the acrosomal reaction. Moreover PDE1A
location in the midpiece and the principal piece of the
flagellum is also consistent for a probable role of the above
isoform in the development of sperm motility and sperm
capacity to undergo hyperactivation. In earlier studies,
however, Cheng and Boettcher [120] using as a method
both polyacrilamide gel electrophoresis and
DEAE-cellulose column chromatography have proven the presence
of at least five isoenzymes of PDEs in human semen.
Richter et al. [121] have demonstrated the presence of
mRNA for six PDE types/subtypes in ejaculated human
spermatozoa. More specifically using the RT-PCR as a
method to detect the mRNA transcripts of PDE subtypes,
the authors found strongly specific bands for PDE1B,
PDE3B, PDE4A, PDE4B, and PDE8 while amplification products of PDE-1A/C, -2, -3A,
-4C, and -5 were observed in a part of the samples as weak signals.
However it is not clear whether the mRNA transcripts are
products of a de novo synthesis in ejaculated
spermatozoa or whether they are synthesized at an earlier stage of
spermatogenesis and then are stored in
ribonucleoprotein particles. Moreover it should be emphasized that the
rate of hydrolysis of cyclic nucleotides in spermatozoa
is much faster (9 to 600 fold) than the rate of cyclic
nucleotides formation suggesting that the PDE have a
dominant role in the control of the concentration of
cyclic nucleotides in spermatozoa [120].
7 Development of PDE5 inhibitors for the
management of ED
Sexual dysfunction represents in many societies, a
taboo and scientific research on this field did not expand
as it happened in other medical fields. With the
introduction in the market of the first effective orally
administered medicine for the treatment of ED sildenafil, research
efforts for the treatment of ED have become a priority
for several pharmaceutical companies. Sildenafil and the
substances vardenafil and tadalafil, which have been
developed later, are known as PDE5 selective inhibitors. In
adittion, several other potent PDE5 inhibitors with a variety
of scaffolds have been developed. For example quinazoline
derivatives [122_124], phthalazine derivatives [125, 126],
tetracyclic diketopiperazines [127], indoles [128],
pyrido[3,2,1-jk]carbazoles [98] represent the results of research
efforts in this field.
Sildenafil as oral treatment for the ED was approved
by the FDA in USA on March 1998. Because of the mechanism of its action, pharmacokinetics, and
metabolism, sildenafil is contraindicated in patients
receiving organic nitrates or NO donors. Moreover the
administration of this medicine should be avoided in
patients with hepatic or renal impairment. In
vitro studies have indicated that sildenafil is a weak inhibitor of
cytochrome P450. Sildenafil administration to hypertensive
patients has shown a mean additional reduction of
supine blood pressure when sildenafil was administrated
with amlodipine. Patients with cardiovascular diseases
under treatment with medicines different to nitrates, such
as ACE inhibitors, α-adrenoceptor or β-adrenoceptor
blockers, calcium channel blockers or diuretics can safely
receive sildenafil as well. In fact it has been
demonstrated by Kloner et al. [129] that sildenafil does not have
a synergic effect on blood pressure with the above
antihypertensive agents. Similarly, a significant
improvement in satisfaction with their sexual life was reported in
patients with spinal cord injury [130] as well as in
patients with sexual dysfunction due to treatment with
abtidepressants. The most frequently reported side
effects of sildenafil are headache (7%_25%), facial
flushing (7%_34%), nasal congestion (4%_19%), dyspepsia
(1%_11%), and visual effects (1%_6%) [131_134] were
also consistent with the control trials [135]. Approximately
0%_10% of men who receive sildenafil discontinue the
treatment due to the severity of side effects [131_134].
Vardenafil was the second selective PDE5 inhibitor
developed in the market. It received an approval letter
from the FDA on September 2001. Its chemical
structure is very similar to that of sildenafil. However vardenafil
has been proven that it has lower in vitro
IC50 value (concentration of the medicine which inhibits 50% of
the PDE5 activity) compared with sildenafil. Vardenafil
should not be administrated in patients who receive
treatment with organic nitrates, because vardenafil may
potentiate their hypotensive effects. For this reason this
compound may be contraindicated in patients receiving
α-blockers (FDA approval history). In
vitro studies have shown that vardenafil is a weak inhibitor of cytochrome
P450. Common side effects are headache, flushing,
dyspepsia, and rhinitis [136]. No changes in vision have
been reported [137, 138]. However the side effects of
vardenafil improve to a dose dependent-manner over time
and gradually there is an attenuation of the severity of
the side effects with continued treatment [139_141].
Tadalafil is the most recently developed selective
PDE5 inhibitor which was submitted to the FDA for
approval on April 2002. Its molecular structure differs
significantly from those of sildenafil and vardenafil.
Moreover concentrations of tadalafil which inhibit effectively
PDE5 have a lower inhibitory effects in PDE6 compared
with the other two approved selective PDE5 inhibitors.
Indeed, tadalafil has not been shown to have any visual
side effects [142, 143]. In a recent study Weeks
et al. [144] showed that tadalafil has a 40-fold selectivity ratio
for PDE5 over PDE11A4 whereas sildenafil and vardenafil
demonstrate selectivity ratios for PDE5 over PDE11A4
1 000-fold and 9 000-fold, respectively. It appears that
PDE11 is inhibited by tadalafil within the therapeutic range
of tadalafil [144]. The eventual adverse effects of tadalafil
through the inhibition of PDE11 are not yet clearly
established [145]. The back and muscle pain reported
relatively often by men who receive tadalafil may be mediated
through the inhibition of PDE11 [142, 146].
Several investigators have focused their effects to
evaluate the pattern of expression of PDE11 in the human.
The results of these studies demonstrated the presence
of PDE11A4 protein in the prostate, pituitary, heart, and
liver [147]. The above findings are partially in
agreement with other studies evaluating the distribution of
PDE11A mRNA and that of the PDE11A protein [96,
148_150]. Questions have been raised on the effect of tadalafil
on testicular function, germ cell viability, and
characteristics of prostatic fluid [117].
Tadalafil has a much longer half-life time than
sildenafil and vardenafil achieving a period of efficacy of
up to 36 h [146]. The onset of the action of tadalafil is
rapid. Padma-Nathan et al. [151] have reported effects
of tadalafil within a period of 20 min. Similarly with the
other PDE5, selective inhibitors, tadalafil should not be
administered in patients taking nitrates. Clinical trials
investigating the effect of tadalafil in patients under
antihypertensive treatment with angiotensin-converting enzyme
inhibitors, calcium antagonists, thiazide diuretics,
β-blockers, ARBs, loop diuretics, or α-blockers have
revealed no statistically significant difference in blood
pressure profiles between tadalafil and placebo treatment
groups [152]. Headache, dyspepsia, muscle pain and
back pain are the typical side effects of this medicine.
Moreover adverse events like infection, nasal congestion,
and spontaneous erections have also been reported in the
literature [142].
8 Effects of non-selective PDE inhibitors on sperm
parameters
The in vivo and in vitro influence of PDE inhibitors
on the sperm parameters has been the focus of several
research efforts. The stimulating effect of the PDE
inhibition on sperm motility may suggest an association
between the intracellular levels of cytosolic nucleotides and
the sperm ability to move [22, 153]. However the
majority of studies evaluating the effects of PDE inhibitors
on spermatozoa employed non-selective PDE inhibitors
which have been used for many years in clinical trials.
Only few of the above studies have employed the
selective PDE5 inhibitors sildenafil, vardenafil, or tadalafil.
Many chemical molecules have been studied aiming
to stimulate human sperm functions in vivo or
in vitro. These molecules include poorly defined biologic materials,
(e.g., serum, peritoneal fluid, and follicular fluid) as well
as defined chemical agents such as adenosine analogues,
progesterone, and methylxanthines [154, 155].
Methylxanthines belong to the first generation of PDE inhibitors
and represent a chemical group of drugs derived from
xanthine (a purine derivative) including those among
others: theophylline, caffeine, and pentoxifylline. Their
beneficial effect on sperm motility has been recognised
since 1970 [156_159]. Jaiswal and Majumder [160]
investigating the role of theophylline demonstrated that this
PDE inhibitor markedly increaded (10-fold or greater)
the motility of spermatozoa derived from proximal-corpus, mid-corpus, distal-corpus, and proximal-cauda
epididymides. Caffeine has also been shown to increase
sperm motility and metabolism when it is added to the
semen [18, 161]. However this compound promotes the
spontaneous sperm acrosomal reactions. This effect of
caffeine on sperm acrosome counteracts the benefits
from its role as a motility stimulant [23]. Pentoxifylline
(PTX), is the most widely non-selective PDE inhibitor
used [154, 162_168]. Although its beneficial effect on
the outcome of in vitro fertilization (IVF) trials in
normozoospermic subjects and oligo-asthenozoospermic
patients is well documented [169_172] the efficacy of
its oral administration to increase sperm fertilizing ability
is controversial [168]. PTX has been considered to
stimulate flagellar motility by increasing sperm intracellular
cAMP [173_176] as well as by reducing sperm
intracellular superoxide anion and DNA damaging reactive
oxygen species [177, 178]. The improvement of sperm
fertilizing ability in vitro may be due to an effect of PTX on
sperm motion characteristics and not due to an increase
in the number of motile spermatozoa [179]. In
particular PTX appears to increase significantly beat cross
frequency, curvilinear velocity, and percentage of
hyperactivated spermatozoa [18, 154, 164, 166,
180_185]. A beneficial effect of PTX on sperm-oocyte
binding assay has been described [186].
It should be mentioned that PDE4 inhibitors, as well,
increase sperm motility. PDE4 inhibitors do not have an
obvious effect on the sperm acrosome reaction. On the
other hand PDE1 inhibitors seem to selectively stimulate
the acrosome reaction [22].
9 PDE5 selective inhibitors and sperm parameters:
in vivo studies
In a double-blinded, four-period, two-way,
crossover study encompassing 16 sexual healthy male
volunteers, Purvis et al. [187] examined the effect of sildenafil
on sperm motility and morphology parameters. The
authors compared a 100-mg dose of sildenafil with placebo.
Both sildenafil and placebo administered as single oral
doses for two periods separated by a washout period of
at least 5_7 days. Sildenafil and sildenafil's metabolite
concentrations were measured in a sample of semen collected 4-h post-administration and in several samples
of blood collected during the first hours after sildenafil
administration. The authors reported a lack of effect of
sildenafil on sperm motility. In fact the authors observed
no significant differences between the sildenafil group
and the placebo group for the percentage of motile
spermatozoa, the percentage of static spermatozoa, the
percentage of rapidly moving spermatozoa, and the
percentage of progressively moving spermatozoa. Mean
values of sperm count, morphology, and viability, as well
as seminal plasma volume and viscosity were not
significantly different between the placebo group and the
control group. Mean semen concentrations of sildenafil were
approximately 18% of the mean plasma concentrations
at 1.5 h and 4 h after the sildenafil administration. The
mean sildenafil metabolite concentrations in the semen at
the same periods after sildenafil administration were 5%
(of the plasma concentration) and 15% (of the plasma
concentration), respectively.
The above study by Purvis et al. [187] has
confirmed earlier findings published by Aversa et al.
[188]. The authors have conducted a prospective double-blind,
placebo-controlled, cross-over, two-period-investigation
study, embracing 20 male subjects, which were treated
with sildenafil or placebo. After a washout period of 7
days all subjects were crossed over to receive the
alternative treatment. The authors found no statistically
significant variations in the mean values of sperm number,
sperm motility, and percentage of abnormal
spermatozoa between the two groups. Evaluating the erectile
function and the sexual behaviour in the two groups the
authors reported that while the penile haemodynamic
parameters during erection were not statistically different
between the two groups, the post-ejaculatory refractory
period was significantly reduced in the sildenafil group.
The authors emphasized the potential usage of sildenafil
in assisted reproductive programs when a temporary ED
may occur due to the stress and the psychological
pressure for semen production. The last suggestion has also
been expressed earlier by Tur-Kaspa et al. [189] who
reported his experience on the usage of sildenafil in men
with proven erectile dysfunction during assisted
reproductive technologies (ART) cycles. The stress and
psychological pressure for semen collection becomes larger
if more than one semen samples are necessary during
the day of oocyte pick-up.
In contrast to this study by Aversa et
al. [188] a positive effect of sildenafil on sperm kinematics was
proven. In a prospective double-blind, placebo-controlled,
crossover, two-period-administration, clinical
investigation du Plessis et al. [190] determined the effect of
in vivo sildenafil citrate administration and
in vitro 8-Bromo (Br)-cGMP treatment on semen parameters and sperm
function. Twenty healthy male subjects randomly were
asked to ingest a single dose of 50-mg of sildenafil or
placebo. All the subjects were crossed over to receive
the alternative treatment after a washout period of seven
days. The authors reported no significant differences in
the percentage of spermatozoa with progressive motility
and in the sperm track velocity, sperm amplitude of
lateral head displacement, sperm beat cross frequency,
sperm straightness and sperm linearity between the two
groups. However borderline statistical significant
differences were observed in sperm smoothed path
velocity and sperm straight-line velocity. In addition there
was a statistically significant increase in the percentage
of rapidly moving spermatozoa after sildenafil administration. An increase in the outcome of sperm
oocyte binding assay (SOBA) was found after sildenafil
administration. Similar effects on sperm kinetics were
noted after 8-Br-cGMP treatment due to elevation in
intracellular cGMP levels. An increase of 134% in SOBA
outcome was demonstrated after 8-Br-cGMP treatment.
The authors speculated that these increases in sperm
ability to bind to the oocyte could possibly be explained
by the fact that more spermatozoa became rapidly motile
after sildenafil administration, and thus the chances for
them to bind with the oocyte increase. The authors have
concluded that sildenafil may increase some sperm
movement parameters as well as the sperm-oocyte binding.
In an open-label pilot study Jannini et
al. [191] investigated the effect of 50-mg orally administered
sildenafil in a group of sexual healthy men who
participated in an intrauterine artificial insemination program or
planned sexual intercourseto perform a post-coital test
(one or two tests). They found no effect of sildenafil
administration in sperm motility, in the sperm concentration, or in the total number of spermatozoa
ejaculated. Similarly no effect of sildenafil
administration was demonstrated in the percentage of nonlinear
progressive motile spermatozoa. However, a significant
increase was seen in the linear progressive motility due to
sildenafil administration. In addition, the administration
of sildenafil before the second postcoital test had
positive effects on the sperm number and the sperm motility
in the cervical mucus. The authors have recommended
the administration of sildenafil prior to semen collection
and performance of ART in order to reduce the stress
that is experienced by the male in the ejaculation room of
the infertility clinic. Similar conclusions have been raised
by the same group of investigators in an earlier study
[192]. However in that earlier study the authors did not
demonstrate effects of sildenafil on the linear
progressive sperm motility. The authors suggested that sildenafil
administration has a role in the reduction of the
ejaculation associated stress. According to the authors, sildenafil
administration results in an ejaculation with higher sexual
satisfaction and a subsequent increased number of good
quality spermatozoa in the semen. The importance of
the positive effects of sexual satisfaction and orgasm on
the semen quality and sperm fertilizing capacity was
emphasized in another study comparing masturbation
with videotaped sexual images and without videotaped
sexual images. Masturbation with videotaped sexual
images resulted in recovery of spermatozoa of greater
fertilizing potential [193]. In addition in a similar report
Sofikitis and Miyagawa [194] demonstrated improved
spermatozoal motility in the semen samples collected via
sexual intercourse versus masturbation in infertile men.
Sofikitis and Miyagawa [194] suggested that the higher
the sexual stimulation is, the larger the prostatic
secretory function is with an overall result of better sperm
motility. In addition Sofikitis and Miyagawa [194]
suggested that the higher the sexual stimulation is, the larger
the vas deferens loading during ejaculation is. The latter
suggestion is supported by a study showing that restraint
of bulls or falls mounts before semen collection can
increase the number of motile spermatozoa by as much as
50% [195]. Also in bulls, it has been suggested that
oxytocin and prostaglandin F2a may be at least partly
responsible for the improvement of the ejaculate after sexual
stimulation [196, 197]. The effects of sildenafil on
semen quality and male accessory genital gland function
were the aim of a study conducted by Kanakas
et al. [198]. Three semen samples were collected from each
of 13 oligozoospermic infertile men without sildenafil
treatment and after sildenafil treatment (same men). The
authors evaluated the total sperm count, the percentage
of motile sopermatozoa and, the percentage of
morphologically normal spermatozoa in all samples. The first,
second, and third semen sample collected from each
patient via each method were processed for evaluation
of α-glucosidase (marker of epididymal function),
fructose (marker of seminal vesicular function), and citrate
(marker of prostatic secretory function),
respectively. The authors found [198] that the mean values of total sperm
count, percentage of motile spermatozoa and seminal
plasma citrate levels were significantly larger in semen
samples collected after sildenafil administration compared
with semen samples collected without prior usage of
sildenafil. No significant differences were demonstrated
in the markers of the secretory function of seminal
vesicles. The authors have suggested that the differences
in the markers of prostatic secretions between the two
groups of semen samples may be due to the greater sexual
stimulation prior to/during ejaculation after sildenafil
administration. It appears that sildenafil treatment
promoted prostatic secretory function and increased
loading of the vas deferens. The authors have also stated
that the increase in prostatic secretory function after
administration of sildenafil provides an explanation for the
enhanced sperm motility. This is consistent with other
reports which have demonstrated that secretory
dysfunction of the male accessory genital glands due to prostatic
infections impairs male fertility potential [199]. The
seminal fluid [200] may contain factors that are not
absolutely essential to fertilization. However, optimal
concentrations of prostatic secretory markers may provide
an environment ideal for sperm motility and transport
[194]. Citrate, the major anion of human seminal fluid is
important for maintaining the osmotic equilibrium of the
prostate [201]. A zinc compound (probably a salt) is a
potent antibacterial factor which is excreted from the
human prostate providing for the high content of zinc in
the sperm nucleus and contributes to the stability of the
quaternary structure of the sperm nucleus chromatin
[202]. Spermine, a substance in seminal fluid, secreted
by the prostate, is also correlated with the sperm count
and motility and its concentrations in men with chronic
bacterial prostatitis have been shown to be decreased
[203]. Semen cholesterol content is synthesized in
human prostate and is important for stabilizing the sperm
membrane against temperature and environmental shock
[203]. Thus enhancement of the concentrations of
prostatic secretions in the seminal samples collected after
sildenafil administration may explain the higher sperm
motility profiles in these samples.
Few recent studies support the findings of the above
investigation by Kanakas et al. [198]. Ali
et al. [204] administered 100-mg sildenafil citrate in diabetic
neuropathic patients. The authors found that sperm motility
and semen volume were increased in men treated with
sildenafil. On the other hand sperm morphology remained
unaffected. In adittion the authors proposed that sildenafil
administration is associated with an improvement in the
entire smooth musculature of the male reproductive tract
which has been altered due to neuropathy. Sildenafil
administration resulted in reduction in the excessive
accumulation of interstitial collagen and calcification in the
smooth muscles which had resulted in bladder atonia in
the diabetic men. The overall result in diabetic men was
partial or total retrograde ejaculation associated with
decreased sperm motility. In this study sildenafil
administration improved sperm motility. On the other hand the
authors noticed that long time sildenafil treatment was
associated with a significant decrease in total sperm
output and sperm concentration.
Pomara et al. [205] performed a prospective,
double-blind, randomized, crossover study describing the acute
effect of both sildenafil (50 mg) and tadalafil (20 mg) in
young infertile men. Eighteen young infertile men were
asked to ingest a single dose of either sildenafil or tadalafil
in a blind, randomized order. Semen samples were
collected one or two hours after the administration of each
PDE5 inhibitor. The authors reported a significant
increase in sperm progressive motility in semen samples
collected after sildenafil administration compared with
semen samples collected prior to sildenafil administration.
The authors have suggested that the stimulatory result
of sildenafil on sperm motility may be due to a direct
action of sildenafil on sperm mitochondria and calcium
channels. Another report demonstrated that PDE5A is
localized mainly to sea urchin sperm flagella regulating
intracellular cGMP levels [206]. Thus a direct effect of
sildenafil on sperm flagella cannot be ruled out [206].
Interestingly, the study by Pomara et al. [205] revealed
a significant decrease in the sperm motility after a single
dose of tadalafil [205]. These latter findings are
inconsistent with an earlier study conducted by Hellstrom and
colleagues [142] who investigated the effects of tadalafil
on semen characteristics and serum concentrations of
reproductive hormones of healthy men and men with mild erectile dysfunction. Hellstrom
et al. [142] performed two randomized, double-blind, placebo controlled,
parallel group studies (one study for a 10-mg dose tadalafil
and one study for a 20-mg dose tadalafil) enrolling 204
subjects in the 10-mg tadalafil study and 217 subjects in
the 20-mg tadalafil study. The investigators assessed
the effect of daily tadalafil or placebo administration for
six months on semen samples and serum levels of
reproductive hormones (testosterone, LH and
follicle-stimulating hormone). The investigators demonstrated that in
each study the proportion of participants with a 50% or
greater decrease in sperm concentration was relatively
small and similar for the placebo group and the 10
mg-tadalafil group or the 20-mg tadalafil group. Similarly
there were no significant alterations in sperm
morphology or sperm motility after treatment with 10 mg or
20 mg tadalafil. The authors demonstrated that there were no
significant alterations in the serum levels of reproductive
hormones after tadalafil administration concluding that
administration of tadalafil at doses of 10 mg and 20 mg
for 6 months did not adversely affect testicular
spermatogenesis process or serum levels of reproductive
hormones. However other investigators emphasise their
dilema concerning the administration of tadalafil on a daily
basis, as they believe that up today the available data
confirming the safety of tadalafil administered on a daily
basis are not yet sufficient, particularly in high-risk patients
[205, 207].
Bauer et al. [208] performed a randomized, placebo
control, double-blind, crossover study to determine the
effects of a single dose of vardenafil 20 mg on indices of
testicular function. Sixteen healthy males participated in
this study. The scientists found no statistically
significant effects of tadalafil on sperm motility, sperm
concentration, sperm viability, and sperm
morphology.
In another study, Grammeniatis et al. [209]
evaluated the effects of vardenafil administration (10 mg) on
male accessory genital gland function. Vardenafil
administration increased the secretory function of prostate.
In contrast, there were no effects of vardenafil
administration on the secretory function of seminal vesicles and
epididymis. In addition, the investigators noted that
semen samples from infertile men treated with 10 mg of
vardenafil in a daily basis for at least 45 days presented a
significantly larger total number of spermatozoa,
quantitative sperm motility, qualitative sperm motility,
percentage of morphologically normal spermatozoa, semen
citrate concentration, and semen acid phosphatase
concentration compared with semen samples from the same
individuals collected prior to vardenafil administration.
The authors suggested that vardenafil stimulated the
prostatic secretory function increasing the quantitative and
qualitative motility of spermatozoa. Moreover the
enhanced sexual satisfanction during ejaculation due to
vardenafil administration has been thought to be the
reason for an increased loading of the vas deferens and the
subsequent significant increase in the total number of
spermatozoa per ejaculate. The significant increase in
the percentage of morphologically normal spermatozoa
may be attributable to the enhancement of prostatic
secretory function due to vardenafil administration since it is
known that optimal prostatic secretory function
regulates the osmotic equilibrium of the seminal plasma
decreasing the percentage of spermatozoa that undergo
osmotic shock and morphological abnormalities.
10 PDE5 selective inhibitors and sperm parameters:
in vitro studies
After the introduction of sildenafil in the market,
several studies have evaluated the in vitro effects of this
compound on sperm parameters. Burger et
al. [210] in an ex vivo study investigated the effect of sildenafil on
the motility, viability, membrane integrity, and functional
capacity of human spermatozoa. The above spermatozoal parameters were evaluated on the spermatozoa of
both healthy donors (n = 6) and clinically infertile men
(n = 6). Separate aliquots were incubated for 0 h, 1 h and
3 h in the absence or presence of sildenafil (125 ng/mL,
250 ng/mL, and 750 ng/mL), PTX (as a positive control),
or Ham's medium (as a reagent control). The authors
have reported no statistically significant effect of sildenafil
on sperm viability, sperm motility, and sperm forward
progression after incubation of spermatozoa with
various doses of sildenafil. However the authors noted a
marked decrease of sperm membrane integrity in
spermatozoa of infertile patients treated with sildenafil. This
should be taken into consideration when treatment with
sildenafil is planed in subfertile couples with a male
factor infertility. Finally, in this study, sperm penetration
assay data suggested that there is neither a beneficial nor
a detrimental effect of sildenafil on its outcome.
Similarly in another study the group of Andrade and
colleagues [33] attempted to evaluate a direct effect of
sildenafil and phentolamine on sperm motility. Using
samples of either unwashed or washed spermatozoa of
10 men, the investigators added directly to the samples
sildenafil at a concentration of 20 mg/mL or
phentolamine in various doses and incubated the samples for 10
and 30 min. The authors demonstrated a dose-related
inhibition of sperm motility in sperm samples treated with
phentolamine whereas sildenafil (at a concentration of
200 μg/mL) did not adversely affect sperm motility
either in unwashed or washed sperm. In contrast the
highest dose of sildenafil (2 000 μg/mL) reduced the sperm
motility approximately 50%. However, it should be
emphasized that at this concentration sildenafil caused a
marked acidification of the medium which may be the
reason for the reduced sperm motility [211]. Thus a
direct effect of a high dose of sildenafil on sperm
motility cannot be strongly supported.
In an experimental study Su and Vacquier [212]
determined the motility, chemotaxis, and the acrosome
reaction of sea urchin sperm. By cloning and
characterizing a sea urchin sperm PDE (suPDE5) which is an
ortholog of human PDE5 the authors found that
phospho-suPDE5 localizes mainly on sperm flagella and the PDE5
phosphorylation increases when spermatozoa contact the
jelly layer that surrounds the eggs. Since the
in vitro dephosphorylation of suPDE5 decreased its activity the
authors suggested that PDE5 inhibitors such as sildenafil
on sperm motility may inhibit the activity of suPDE5 and
increase sperm motility.
A concentration-dependent stimulatory effect of
sildenafil on sperm motility was also demonstrated
recently by Mostafa [213] when 85 semen specimens from
asthenozoospermic patients were exposed to different
five concentrations of sildenafil (4.0 mg/mL, 2.0 mg/mL,
1.0 mg/mL, 0.5 mg/mL, 0.1 mg/mL). However, the
evaluation of sperm motility in this study was only 3 hours
after the spermatozoa exposure to the medicine.
Lefièvre et al. [214] investigated whether PDE5 is
present in human spermatozoa and whether sildenafil
affects sperm function. The authors showed that this
PDE5 inhibitor stimulates human sperm motility with an
increase in intracellular cAMP suggesting an inhibitory
action on a PDE that is different to PDE5. The authors
attempted to inhibit the enzyme activity in washed
spermatozoa using increasing concentrations of sildenafil or
dipyridamole. The latter substances are selective
inhibitors of cGMP-specific PDE5. Both compounds
suspended the enzyme activity successfully. However
sildenafil exhibited an inhibition potential that was four
times higher. In semen sampes incubated with
increasing concentrations of sildenafil, the authors noted a
dose-dependent increase in intracellular cAMP levels. Sildenafil
at 30 µmol/L, 100 µmol/L, and 200 µmol/L triggered
capacitation of washed spermatozoa. Capacitated
spermatozoa underwent an acrosome reaction when
challenged with lysophosphatidylcholine (LPC) alone or LPC
plus PDE inhibitors. However capacitated spermatozoa
did not undergo acrosomal reaction when they were
challenged with sildenafil or another PDE inhibitor alone. The
investigators have suggested that sildenafil might act on
PDEs other than type 5. They have also suggested that
sildenafil in high concentrations as high as 30, 100 and
200 µmol/L acts no longer as type-5 specific and
probably partially inhibits other PDEs present in
spermatozoa such as PDE1 and PDE4 which have high affinity
for cAMP [215]. This may explain the intracellular
increase in cAMP in spermatozoa incubated with high doses
of sildenafil.
In another study conducted by Cuadra and colleagues
[216] the effect of sildenafil on sperm motility and on
acrosomal reaction was determined. Spermatozoa were
exposed to sildenafil at either 0 nmol/L, 0.4 nmol/L,
4.0 nmol/L, or 40 nmol/L, simulating in this way the
post-administration concentrations of sildenafil in the
semen and plasma. The scientists observed increased
sperm motility parameters in the presence of 0.4 nmol/L
sildenafil compared with the control sample four hours
after the exposure to sildenafil. However, the motility
parameters decreased 48 h after the exposure to sildenafil.
Spermatozoa exposed to higher concentration of
sildenafil (40 mol/L) showed decreased motility parameters.
In this study, sildenafil affected the sperm acrosome
reaction with an increase of almost 50% compared to the
control samples. It is known that cGMP directly opens
cyclic nucleotide-gated channels for calcium entry into
the spermatozoa, initiating the acrosome reaction. In the
same way cGMP regulates calcium entry into microdomains along the sperm flagellum affecting sperm
motility. Since PDE5 hydrolyzes cGMP, inhibition of
PDE5 by sildenafil citrate enhances the effects of cGMP
on sperm motility and sperm acrosome reaction. The
data provided by the authors suggest a dual mechanism
for PDE5 inhibition with a stimulatory effect on sperm
motility when PDE5 is moderately inhibited; however,
extensive inhibition of PDE5 leads to decreased sperm
motility.
Another group of researchers [217] attempted to
determine the influence of sildenafil on sperm motility or
acrosome reaction. Semen samples from fifty-seven
unselected men with asthenozoospermic profiles were
prepared and then exposed to 0.67 μmol/L of sildenafil
which is equivalent to the plasma concentration of
sildenafil, one hour after oral ingestion of 100 mg of
sildenafil. The authors found that both the number and
the velocity of progressively motile spermatozoa were
significantly increased. They also noticed that sildenafil
caused a significant increase in the proportion of
acrosome-reacted spermatozoa suggesting that sildenafil
may adversely affect male fertility. The scientists
suggested that the raised levels of cGMP as a result of the
inhibitory effect of sildenafil affect many sperm
functions such as calcium transport into spermatozoa.
Altered levels of intracellular calcium may potentially
affect sperm motion and an energy-dependent influx of
calcium into the sperm cell which may be responsible
for initiation of the acrosome reaction. In a case report
of sildenafil administration for semen collection for
human-assisted reproduction the investigators failed to
fertilize oocytes despite the intracytoplasmic injection of the
sperm [189]. Although this fertilization failure was
attributed to the advanced age of oocytes due to the delay
in obtaining the semen sample, a deleterious effect of
sildenafil on sperm function can not be excluded.
The effects of tadalafil on human sperm motility in
vitro have been investigated. Mostafa [218] assessed
the ability of tadalafil on human sperm motility in 70
asthenozoospermic semen specimens. The semen samples
were exposed to three different concentrations of tadalafil
(4.0, 1.0, 0.5 mg/mL) and it was found sperm samples
treated with 4 mg/mL tadalafil solution demonstrated a
significant decrease in sperm motility compared with the
controls samples whereas sperm samples treated with
1.0 or 0.5 mg/mL tadalafil solution demonstrated a
significant increase in sperm progressive forward motility. The
authors suggested that the concentration of tadalafil plays
an important role in the degree of sperm enhancement.
The normal mammalian sperm motility seems to be
governed predominantly by the cAMP/PKA pathway and
calcium signalling pathway, whereas mechanisms
involving heterotrimeric and small G-protein have also been
entailed the regulation of sperm motility [19, 219, 220].
It should be emphasized that cAMP may also act through
PKA independent pathways. In fact, Burton et
al. [221] speculated that cAMP may activate a cyclic
nucleotide-gated ion channel in spermatozoa and/or
cAMP-mediated guanine nucleotide exchange factors in testes,
providing these ways as alternative pathways for the
PKA-mediated regulation of flagellar motility. The dual effect
of in vitro usage of tadalafil on sperm motility in regard
of its concentration in the semen could be explained by
one or more of these pathways.
Alternatively, the effect of tadalafil on sperm motility
may be related also to the inhibitory effect of this
compound on PDE11. In fact, PDE11 is highly expressed in
the testis, prostate, and developing spermatozoa even if
its physiological role is not known. Wayman et
al. [222] in an effort to investigate the role of PDE11 in
spermatozoa physiology, retrieved spermatozoa from PDE11
knockout mice (PDE11-/-). The authors found a reduced
sperm concentration, decreased forward motility, and
lower percentage of alive spermatozoa. In adittion
spermatozoa from PDE11-/- animals demonstrated increased
premature/spontaneous capacitance. These data suggest
a role for PDE11 in spermatogenesis and fertilization
potential.
Fisch et al. [22] showed that PDE4 inhibitors
enhanced in vitro sperm motility over controls without
affecting the acrosome reaction. On the othe hand PDE1
inhibitors selectively stimulated the acrosome reaction.
Gathering the results of the above ex
vivo studies we may discern a dose dependent effect of sildenafil and
tadalafil on sperm motility. In fact this effect seems to
be enhanced at low doses but it may be reduced at high
concentrations. Moreover sildenafil appears to exhibit a
stimulatory effect on sperm capacitation, acrosome
reaction, and sperm-oocyte binding. Doubtless, further
investigations are required to evaluate the mechanisms
of the effects of PDE5 selective inhibitors on sperm
motility and sperm fertilization capacity. To elucidate
whether or not PDE inhibitors one day will be used as an
adjunct tool for male infertility treatment, more studies
are necessary.
References
1 Rall TW, Sutherland EW. Formation of a cyclic adenine
ribonucleotide by tissue particles. Biol Chem 1958; 232: 1065_76.
2 Hurley JH. The adenylyl and guanylyl cyclase superfamily. Curr
Opin Struct Biol 1998; 8: 770_7.
3 Waldman SA, Murad F. Cyclic GMP synthesis and function.
Pharmacol Rev 1987; 39: 163_96.
4 Denninger JW, Marletta MA. Guanylate cyclase and the NO/cGMP
signaling pathway. Biochim Biophys Acta 1999; 1411: 334_50.
5 Wedel BJ, Garbers DL. The guanylate cyclase family at Y2K.
Annu Rev Physiol 2001; 63: 215_33.
6 Liu Y, Ruoho AE, Rao VD, Hurley JH. Catalytic mechanism of
the adenylyl and guanylyl cyclases: modeling and mutational
analysis. Proc Natl Acad Sci USA 1997; 94: 13414_9.
7 Garbers DL, Lowe DG. Guanylyl cyclase receptors. J Biol Chem
1994; 269: 30741_4.
8 Barr CS, Rhodes P, Struthers AD. C-type natriuretic peptide.
Peptides 1996; 17: 1243_51.
9 Forte LR, London RM, Freeman RH, Krause WJ. Guanylin
peptides: renal actions mediated by cyclic GMP. Am J Physiol
2000; 278: F180_F191.
10 Moreland RB, Hsieh G, Nakane M, Brioni J. The biochemical and
neurologic basis for the treatment of male erectile dysfunction. J
Pharmacol Exp Ther 2001; 296: 225_34.
11 Cellek S, Moncada S. Nitrergic control of peripheral
sympathetic responses in the human corpus cavernosum: a comparison
with other species. Proc Natl Acad Sci USA 1997; 94: 8226_31.
12 Andersson KE. Pharmacology of penile erection. Pharmacol
Rev 2001; 53: 417_50.
13 Visconti PE, Moore GD, Bailey JL, Leclerc P, Connors SA, Pan
D, et al. Capacitation of mouse spermatozoa. II. Protein
tyrosine phosphorylation and capacitation, are regulated by
cAMP-dependent pathway. Development 1995; 121: 1139_50.
14 Leclerc P, de Lamirande E, Gagnon C. Cyclic adenosine 39, 59
monophosphate- dependent regulation of protein tyrosine
phosphorylation in relation to human sperm capacitation and motility.
Biol Reprod 1996; 55: 684_92.
15 Tash JS. Role of cAMP, calcium and protein phosphorylation in
sperm motility. In: Gagnon C, editor. Controls of Sperm Motility:
Biological and Clinical Aspects. Boca Raton, FL: CRC Press
1990. p229_41.
16 Zhung ZH, Zheng RL. Possible role of nitric oxide on fertile and
asthenozoospermic infertile human sperm functions. Free
Radical Res 1996; 25: 347_54.
17 Lewis SE, Donnelly BT, Sterling ES, Kennedy MS. Nitric oxide
synthase and nitric production in human spermatozoa: evidence
that endogenous nitric oxide is beneficial in sperm motility. Mol
Hum Reprod 1996; 2: 873_8.
18 Rees JM, Ford WC, Hull MG. Effect of caffeine and of
pentoxifylline on the motility and metabolism of human
spermatozoa. Reprod Fertil 1990; 90: 147_56.
19 Yanagimachi R. Mammalian fertilization. In: The Physiology
of Reproduction, 2nd edn. Knobil E, Neill JD, editors. Raven
Press, New York. 1994; p189_317.
20 MacLeod JM, Paupard MC, Orr AG. Flagellar-associated
cAMP-dependent protein kinases in mammalian sperm. In: Baccetti B,
eidtor. Comparative Spermatology 20 Years After, Vol 75. Raven
Press, New York. 1991; p397_401.
21 De Jonge CJ, Han HL, Lawrie H, Mack SR, Zaneveld LJ.
Modulation of the human sperm acrosome reaction by effectors of the
adenylate cyclase/cyclic AMP second-messenger pathway. J Exp
Zool 1991; 258:113_25.
22 Fisch JD, Behr B, Conti M. Enhancement of motility and
acrosome reaction in human spermatozoa: differential
activation by type-specific phosphodiesterase inhibitors. Hum Reprod
1998; 13:1248_54.
23 Tesarik J, Mendoza C, Carreras A. Effect of phosphodiesterase
inhibitors, caffeine and pentoxifylline, on spontaneous and
stimulus-induced acrosome reactions in human sperm. Fertil Steril
1992; 58:185_90.
24 Nathan C. Nitric oxide as a secretory product of mammalian
cells. FASEB J 1992; 6: 3051_64.
25 Herrero MB, Perez-Martinez S, Viggiano JM, Polak JM, Gimeno
MF. Localization by indirect immunofluorescence of nitric
oxide synthase in mouse and human spermatozoa. Reprod Fertil
Dev 1996; 8: 931_4.
26 Donnelly ET, Lewis SE, Thompson W, Chakravarthy U. Sperm
nitric oxide and motility: the effects of nitric oxide synthase
stimulation and inhibition. Mol Hum Reprod 1997; 3: 755_62.
27 O'Bryan MK, Zini A, Cheng CY, Schlegel PN. Human sperm
endothelial nitric oxide synthase expression: correlation with
sperm motility. Fertil Steril 1998; 70: 1143_7.
28 Revelli A, Soldati G, Costamagna C, Pellerey O, Aldieri E,
Massobrio M, et al. Follicular fluid proteins stimulate nitric
oxide (NO) synthesis in human sperm: a possible role for NO in
acrosomal reaction. J Cell Physiol 1999; 178: 85_92.
29 Hellstrom W, Bell M, Wang R, Sikka S. Effect of sodium
nitroprusside on sperm motility, viability and lipid peroxidation. Fertil
Steril 1994; 61: 1117_22.
30 Rosselli M, Dubey RK, Imthurn B, Macas E, Keller PJ. Effects of
nitric oxide on human spermatozoa: evidence that nitric oxide
decreases sperm motility and induces sperm toxicity. Hum Reprod
1995; 10: 1786_90.
31 Revelli A, Ghigo D, Moffa F, Massobrio M, Tur-Kaspa I.
Guanylate cyclase activity and sperm function. Endocr Rev
2002; 23: 484_94.
32 Sofikitis N, Miyagawa I, Toda T, Terakawa N. Effects of an
inhibitor of adenylate cyclase on acrosome reaction induced by
protein kinase C activators. Arch Androl 1993; 30: 87_92.
33 Andrade JR, Traboulsi A, Hussain A, Dubin NH.
In vitro effects of sildenafil and phentolamine, drugs used for erectile dysfunction, on
human sperm motility. Am J Obstet Gynecol 2000; 182: 1093_5.
34 Nobunaga T, Tokugawa Y, Hashimoto K, Kubota Y, Sawai K,
Kimura T, et al. Elevated nitric oxide concentration in the
seminal plasma of infertile males: nitric oxide inhibits sperm
motility. Am J Reprod Immunol 1996; 36: 193_7.
35 Beavo JA. Cyclic nucleotide phosphodiesterases: functional
implications of multiple isoforms. Physiol Rev 1995; 75: 725_48.
36 Sonnenburg WK, Seger D, Kwak KS, Huang J, Charbonneau H,
Beavo JA. Identification of inhibitory and calmodulin-binding
domains of the PDE1A1 and PDE1A2 calmodulin-stimulated
cyclic nucleotide phosphodiesterases. J Biol Chem 1995;
270:30989_1000.
37 Maurice DH, Palmer D, Tilley DG, Dunkerley HA, Netherton SJ,
Raymond DR, et al. Cyclic nucleotide phosphodiesterase activity,
expression, and targeting in cells of the cardiovascular system.
Mol Pharmacol 2003; 64: 533_46.
38 Zhao AZ, Yan C, Sonnenburg WK, Beavo JA. Recent advances
in the study of Ca2+/CaM-activated phosphodiesterases:
expression and physiological functions. Signal Transduct Health Dis
1997; 31: 237_51.
39 Florio VA, Sonnenburg WK, Johnson R, Kwak KS, Jensen GS, Walsh
KA, et al. Phosphorylation of the 61-kDa calmodulin-stimulated
cyclic nucleotide phosphodiesterase at serine 120 reduces its
affinity for calmodulin. Biochemistry 1994; 33: 8948_54.
40 Hashimoto Y, Sharma RK, Soderling TR. Regulation of
Ca2+/calmodulin-dependent cyclic nucleotide phosphodiesterase by the
autophosphorylated form of Ca2+/calmodulin-dependent protein
kinase II. J Biol Chem 1989; 264: 10884_7.
41 Kakkar R, Raju RVS, Sharma RK. Calmodulin-dependent cyclic
nucleotide phosphodiesterase (PDE1). Cell Mol Life Sci 1999;
55: 1164_86.
42 Manganiello VC, Tanaka T. Murashima S. Cyclic GMPstimulated
cyclic nucleotide phosphodiesterases. In: Beavo J, Houslay MD,
editors. Isoenzymes of Cyclic Nucleotide Phosphodiesterases.
John Wiley and Sons, New York, 1990; p61_85.
43 Yang Q, Paskind M, Bolger G, Thompson WJ, Repaske DR,
Cutler LS, et al. A novel cyclic GMP stimulated
phosphodiesterase from rat brain. Biochem Biophys Res Commun 1994;
205: 1850_8.
44 Guy J, Rosman A, Timothy J, Martins A, William K, Sonnenburg
B, et al. Isolation and characterization of human cDNAs encoding
a cGMP-stimulated 3', 5'-cyclic nucleotide phosphodiesterase
1. Gene 1997; 191: 89_95.
45 Repaske DR, Corbin JG, Conti M, Goy MF. A cyclic
GMP-stimulated cyclic nucleotide phosphodiesterase gene is highly expressed in
the limbic system of the rat brain. Neuroscience 1993; 56: 673_86.
46 Dickinson NT, Jang EK, Haslam RJ. Activation of
cGMP-stimulated phosphodiesterase by nitroprusside limits cAMP
accumulation in human platelets: effects on platelet aggregation. Biochem
J 1997; 323: 371_7.
47 Mery PF, Pavoine C, Pecker F, Fischmeister R.
Erythro-9-(2-hydroxy-3-nonyl) adenine inhibits cyclic GMP-stimulated
phosphodiesterase in isolated cardiac myocytes. Mol Pharmacol 1995;
48: 121_30.
48 Wunder F, Tersteegen A, Rebmann A, Erb C, Fahrig T, Hendrix
M. Characterization of the first potent and selective PDE9
inhibitor using a cGMP reporter cell line. Mol Pharmacol 2005;
68: 1775_81.
49 Podzuweit T, Nennstiel P, Muller A. Isozyme selective inhibition of
cGMP-stimulated cyclic nucleotide phosphodiesterases by
erythro-9-(2-hydroxy-3-nonyl) adenine. Cell Signal 1995; 7: 733_8.
50 Tang KM, Jang EK, Haslam RJ. Expression and mutagenesis of
the catalytic domain of cGMP-inhibited phosphodiesterase (PDE3)
cloned from human platelets. Biochem J 1997; 323: 217_24.
51 Reinhardt RR, Chin E, Zhou J, Taira M, Murata T, Manganiello
VC, et al. Distinctive anatomical patterns of gene-expression
for cGMP-inhibited cyclic-nucleotide phosphodiesterases. J Clin
Investig 1995; 95: 1528_38.
52 Liu H, Maurice DH. Expression of cyclic GMP-inhibited
phosphodiesterases 3A and 3B (PDE3A and PDE3B) in rat tissues:
differential subcellular localization and regulated expression by
cyclic AMP. Br J Pharmacol 1998; 125: 1501_10.
53 Manganiello VC, Degerman E. Cyclic
nucleotide phosphodiesterases: diverse regulators of cyclic nucleotide signals and inviting
molecular targets for novel therapeutic agents. Thromb Haemost
1999; 82: 407_11.
54 Beavo JA, Reifsnyder DH. Primary sequence of
cyclic-nucleotide phosphodiesterase isozymes and the design of selective
inhibitors. Trends Pharmacol Sci 1990; 11: 150_5.
55 Shakur Y, Holst LS, Landstrom TR, Movsesian M, Degerman E,
Manganiello V. Regulation and function of the cyclic nucleotide
phosphodiesterase (PDE3) gene family. Prog Nucleic Acid Res
Mol Biol 2001; 66: 241_77.
56 Swinnen JV, Joseph DR, Conti M. Molecular cloning of rat
homologues of the Drosophila melanogaster dunce cAMP
phosphodiesterase: evidence for a family of genes. Proc Natl
Acad Sci U S A. 1989; 86: 5325_9.
57 Bolger G, Michaeli T, Martins T, St. John T, Steiner B, Rodgers
L, et al. Mol Cell Biol 1993; 13: 6558_71.
58 Houslay MD. PDE4 cAMP-specific phosphodiesterases. Prog
Nucleic Acid Res Mol Biol 2001; 69: 249_315.
59 Houslay MD, Adams DR. PDE4 cAMP phosphodiesterases:
modular enzymes that orchestrate signalling cross-talk,
desensitization and compartmentalization. Biochem J 2003; 370: 1_18.
60 Conti M, Richter W, Mehats C, Livera G, Park JY, Jin C. Cyclic
AMPspecific PDE4 phosphodiesterases as critical components
of cyclic AMP signaling. J Biol Chem 2003; 278: 5493_6.
61 Souness JE, Aldous D, Sargent C. Immunosuppressive and
anti-inflammatory effects of cyclic AMP phosphodiesterase (PDE)
type 4 inhibitors. Immunopharmacology 2000; 47: 127_62.
62 Zhang HT, Crissman AM, Dorairaj NR, Chandler LJ, O'Donnell
JM. Inhibition of cAMP phosphodiesterase (PDE4) reverses
memory deficits associated with NMDA receptor antagonism.
Neuropsychopharmacology 2000; 23, 198_204.
63 Zhang HT, O'Donnell JM. Effects of rolipram on scopolamine
induced impairment of working and reference memory in the
radial-arm maze tests in rats. Psychopharmacology (Berlin)
2000; 150: 311_6.
64 O'Donnell JM. Antidepressant-like effects of rolipram and other
inhibitors of cyclic adenosine monophosphate phosphodiesterase
on behaviour maintained by differential reinforcement of low
response rate. J Pharmacol Exp Ther 1993; 264: 1168_78.
65 Lin CS, Lau A, Tu R, Lue TF. Expression of three isoforms of
cGMP-binding cGMP-specific phosphodiesterase (PDE5) in
human penile cavernosum. Biochem Biophys Res Commun 2000;
268: 628_35.
66 McAllister-Lucas LM, Haik TL, Colbran JL, Sonnenburg WK,
Seger D, Turko IV, et al. An essential aspartic acid at each of two
allosteric cGMP-binding sites of a cGMP-specific phosphodiesterase.
J Biol Chem 1995; 270: 30671_9.
67 Lin C, Chow S, Lau A, Tu R, Lue TF. Regulation of human PDE5A2
intronic promoter by cAMP and cGMP: identification of a critical
Sp1-binding site. Biophys Res Commun 2001; 280: 693_9.
68 Rybalkin SD, Rybalkina IG, Shimizu-Albergine M, Tang XB,
Beavo JA. PDE5 Is converted to an activated state upon cGMP
binding to the GAF A domain. EMBO J 2003; 22: 469_78.
69 Francis SH, Turko IV, Corbin JD. Cyclic
nucleotide phosphodiesterases: relating structure and function. Prog Nucleic Acid Res Mol Biol
2001; 65: 1_52.
70 Essayan DM. Cyclic nucleotide phosphodiesterases. J Allergy
Clin Immunol 2001; 108: 671_80.
71 Burns ME, Baylor DA. Activation, deactivation and adaptation in
vertebrate photoreceptor cells. Annu Rev Neurosci 2001; 24:
779_805.
72 Koutalos Y, Nakatani K, Yau KW. The cGMP-phosphodiesterase
and its contribution to sensitivity regulation in retinal rods. J
Gen Physiol 1995; 106: 891_921.
73 Nakatani K, Chen C, Yau KW, Koutalos Y. Calcium and
phototransduction. Adv Exp Med Biol 2002; 514 :1_20.
74 Castro Á, Jerez MJ, Gil C, Martinez A. Cyclic nucleotide
phosphodiesterases and their role in immunomodulatory responses:
advances in the development of specific phosphodiesterase
inhibitors. Med Res Rev 2005; 25: 229_44.
75 Daugan Á, Grondin P, Ruault C, Le Monnier de Gouville A, Coste
H, Linget JM. The discovery of tadalafil: a novel and highly
selective PDE5 inhibitor. 2:
2,3,6,7,12,12a-hexahydropyrazino[1',2':1,6]pyrido[3,4-b]indole-1,4-dione analogues. J Med Chem
2003; 46: 4533_42.
76 De Tejada SI, Angulo J, Cuevas P, Fernandez A, Moncada I,
Allona A, et al. The phosphodiesterase inhibitory selectivity
and the in vitro and in vivo potency of the new PDE5 inhibitor
vardenafil. Int J Impot Res 2001; 13: 282_90.
77 Bloom TJ, Beavo JA. Identification and tissue-specific
expression of PDE7 phosphodiesterase splice variants. PNAS 1996;
93:14188_92.
78 Miro X, Perez-Torres S, Palacios JM, Puigdomenech P, Mengod G.
Differential distribution of cAMP specific phosphodiesterase 7A mRNA
in rat brain and peripheral organs. Synapse 2001; 40: 201_14.
79 Glavas NA, Ostenson C, Scaefer JB, Vasta V, Beavo JA. T cell
activation up-regulates cyclic nucleotide phosphodiesterases 8A1
and 7A3. PNAS 2001; 98: 6319_24.
80 Sasaki T, Kotera J, Yuasa K, Omori K. Identification of human
PDE7B, a cAMP-specific phosphodiesterase. Biochem Biophys
Res Commun 2000; 271: 575_83.
81 Gardner C, Robas N, Cawkill D, Fidock M. Cloning and
characterization of the human and mouse PDE7B, a novel
cAMP-specific cyclic nucleotide phosphodiesterase. Biochem Biophys
Res Commun 2000; 272: 186_92.
82 Smith SJ, Brookes-Fazakerley S, Donnelly LE, Barnes PJ, Barnette
MS, Giembycz MA. Ubiquitous expression of phosphodiesterase
7A in human proinflammatory and immune cells. Am J Physiol
Lung Cell Mol Physiol 2003; 284: L279_L289.
83 Nakata A, Ogawa K, Sasaki T, Koyama N, Wada K, Kotera J,
et al. Potential role of phosphodiesterase 7 in human T cell
function: comparative effects of two phosphodiesterase
inhibitors. Clin Exp Immunol 2002; 128: 460_6.
84 Warner-Lambert Company. New Thiadiazoles and their use as
phosphodiesterase 7 inhibitors. 2000; EP 1 193 261 A1.
85 Fisher DA, Smith JF, Pillar JS, St Denis SH, Cheng JB,. Isolation and
characterization of PDE8A, a novel human cAMP-specific
phosphodiesterase. Biochem Biophys Res Commun 1998; 246: 570_7.
86 Soderling SH, Bayuga SJ, Beavo JA. Cloning and
characterization of a cAMP-specific cyclic nucleotide phosphodiesterase.
Proc Natl Acad Sci USA 1998; 95: 8991_6.
87 Wang P, Wu P, Egan RW, Billah MM. Human phosphodiesterase
8A splice variants: cloning, gene organization, and tissue
distribution. Gene 2001; 280: 183_94.
88 Guipponi M, Scott HS, Kudoh J, Kawasaki K, Shibuya K, Shintani
A, et al. Identification and characterization of a novel cyclic
nucleotide phosphodiesterase gene (PDE9A) that maps to
21q22.3: alternative splicing of mRNA transcripts, genomic structure and
sequence. Hum Genet 1998; 103: 386_92.
89 Bonné-Tamir B, Destefano AL, Briggs CE, Adair R, Franklyn B,
Weiss S, et al. Linkage of congenital recessive deafness (gene DFNB10)
to chromosome 21q22.3. Am J Hum Genet 1996; 58:1254_9.
90 Veske A, Oehlmann R, Younus F, Mohyuddin A, Müller-Myhsok
B, Mehdi SQ, et al. Autosomal recessive non-syndromic deafness
locus (DFNB8) maps on chromosome 21q22 in a large
consanguineous kindred from Pakistan. Hum Mol Genet 1996; 5: 165_8.
91 Straub RE, Lehner T, Luo Y, Loth JE, Shao W, Sharpe
L, et al. A possible vulnerability locus for bipolar affective disorder on
chromosome 21q22.3. Nat Genet 1994; 8: 291_6.
92 Detera-Wadleigh SD, Badner JA, Goldin LR, Berrettini WH,
Sanders AR, Rollins DY, et al. Affected-sib-pair analyses reveal
support of prior evidence for a susceptibility locus for bipolar disorder,
on 21q. Am J Hum Genet 1996; 58: 1279_85.
93 Gurling H. Chromosome 21 workshop. Psychiatr Genet 1998;
8: 109_13.
94 Fisher DA, Smith JF, Pillar JS, St Denis SH, Cheng JB. Isolation
and Characterization of PDE9A, a Novel Human cGMP-specific
Phosphodiesterase. J Biol Chem 1998; 273: 15559_64.
95 Phillip J, Mitchell PJ, Malipiero U, Fontana A. Cell type specific
regulation of expression of transcription factor AP-2 in
neuroectodermal cells. Dev Biol 1994; 165: 602_14.
96 Fawcett L, Baxendale R, Stacey P, McGrouther C, Harrow I,
Soderling S, et al. Molecular cloning and characterization of a
distinct human phosphodiesterase gene family: PDE11A. Proc
Nat Acad Sci 2000; 97: 3702_7.
97 Beavo JA, Conti M, Heaslip RJ. Multiple cyclic nucleotide
phosphodiesterases. Molec Pharm 1994; 46: 399_405.
98 Notsu T, Ohzawa N, Nakai Y. Therapeutic agent for erection
failure. Patent 1998; WO9853819.
99 Iwasaki T, Kondo K, Kuroda T, Moritani Y, Yamagata S, Sugiura
M, et al. Novel selective PDE IV inhibitors as antiasthmatic
agents. Synthesis and biological activities of a series of
1-aryl-2,3-bis(hydroxymethyl) naphthalene lignans. J Med Chem 1996;
39: 2696_704.
100 Ukita T, Sugahara M, Terakawa Y, Kuroda T, Wada K, Nakata A,
et al. Novel, potent, and selective phosphodiesterase-4
inhibitors as antiasthmatic agents: synthesis and biological activities
of a series of 1-pyridylnaphthalene derivatives. J Med Chem
1999; 42: 1088_99.
101 Ukita T, Nakamura Y, Kubo A, Yamamoto Y, Takahashi M,
Kotera J, et al. 1-Arylnaphthalene lignan: a novel scaffold for
type 5 phosphodiesterase inhibitor. J Med Chem 1999; 42:
1293_305.
102 Natsugari H, Ikeura Y, Kiyota Y, Ishichi Y, Ishimaru T, Saga
O, et al. Novel, potent, and orally active substance P antagonists:
synthesis and antagonist activity of N-benzylcarboxamide
derivatives of pyrido[3,4-b]pyridine. J Med Chem 1995; 38: 3106_20.
103 Kulkarni SU, Usgaonkar RN. Isocoumarins. Part-XXIII.
Synthesis of Some 6,7-Dimethoxy-3-phenylisocoumarins. J Indian
Chem Soc 1991; 68: 525_6.
104 Marmor MF, Kessler R. Sildenafil (Viagra) and ophthalmology.
Surv Ophthalmol 1999; 44: 153_62.
105 Thompson WJ, Terasaki W, Epstein PM, Strada SJ. Assay of
cyclic nucleotide phosphodiesterase and resolution of multiple
molecular forms of the enzyme. Adv Cyclic Nucleotide Res
1979; 10: 69_92.
106 Whalin ME, Scammell JG, Strada SJ, Thompson WJ.
Phosphodiesterase II, the cGMP-activatable cyclic nucleotide
phosphodiesterase, regulates cyclic AMP metabolism in PC12
cells. Mol Pharmacol 1991; 39: 711_7.
107 Ruppert D, Weithmann KU. HL 725, an extremely potent
inhibitor of platelet phosphodiesterase and induced platelet
aggregation in vitro. Life Sci 1982; 31: 2037_43.
108 Haynes J Jr, Kithas PA, Taylor AE, Strada SJ. Selective
inhibition of cGMP-inhibitable cAMP Phosphodiesterase decreases
pulmonary vasoreactivity. Am J Physiol 1991; 261 (2 Pt 2):
H487_92.
109 Middendorff R, Müller D, Wichers S, Holstein AF, Davidoff MS.
Evidence for production and functional activity of nitric oxide
(NO) in seminiferous tubules and blood vessels of die human
testis. J Clin Endocrinol Metab 1997; 82: 4154_61.
110 Davidoff MS, Middendorff R. The nitric oxide system in the
urogenital tract. In: Steinbusch HW, De Vente J, Vincent SR,
Björklund A, Hökfelt T, editors. Functional neuroanatomy of
the nitric oxide system. Handbook of Chemical Neuroanatomy.
Elsevier: Amsterdam. 2000; p267_314.
111 Middendorff R, Müller D, Mewe M, Mukhopadhyay AK,
Holstein AF, Davidoff MS. The tunica albuginea of the human testis
is characterized by complex contraction and relaxation
activities regulated by cGMP. J Clin Endocrinol Metab 2002;
87:3486_99.
112 Mewe M. Bauer CK. Müller D, Middendorff R. Regulation of
spontaneous contractile activity in the bovine epididymal duct
by cyclic GMP-dependent pathways. Endocrinology 2006;
147:2051_62.
113 Tamura N, Doolittle LK, Hammer RE, Shelton JM, Richardson
JA, Garbers DL. Critical roles of the guanylyl cyclase B receptor
in endochondral ossification and development of female
reproductive organs. Proc Natl Acad Sei USA 2004; 101: 17300_5.
114 Bender AT, Beavo JA. Cyclic nucleotide phosphodiesterases:
molecular regulation to clinical use. Pharmacol Rev 2006;
58:488_520.
115 Fujishige K, Kotera J, Michibata H, Yuasa K, Takebayashi S,
Okumura K, et al. Cloning and characterization of a novel
human phosphodiesterase that hydrolyzes both cAMP and cGMP
(PDE10A). J Biol Chem 1999; 274: 18438_45.
116 Scipioni A, Stefanini S, Santone R, Giorgi M.
Immunohistochemical localisation of PDE5 in Leydig and myoid cells of prepuberal
and adult rat testis. Histochem Cell Biol 2005; 124: 401_7.
117 Francis SH. Phosphodiesterase 11 (PDE11): is it a player in
human testicular function? Int J Impot Res 2005; 17: 467_8.
118 Gray JP, Hardman JG, Hammer JL, Hoos RT, Sutherland EW.
Adenyl cyclase, phosphodiesterase and cyclic AMP of human
sperm and seminal plasma. Fed Proc 1971; 30: 1267_9.
119 Lefièvre L, Lamirande E, Gagnon C. Presence of cyclic
nucleotide phosphodiesterases PDE1A, existing as a stable complex
with calmodulin, and PDE3A in human spermatozoa. Biol Reprod
2002; 67: 423_30.
120 Cheng CY, Boettcher B. Partial characterization of human
spermatozoal phosphodiesterase and adenylate cyclase and the
effect of steroids on their activities. Int J Androl 1982; 5: 253_66.
121 Richter W, Dettmer D, Glander HJ. Detection of mRNA
transcripts of cyclic nucleotide phosphodiesterase subtypes in
ejaculated human spermatozoa. Mol Hum Reprod 1999; 5: 732_6.
122 Takase Y, Saeki T, Watanabe N, Adachi H, Souda S, Saito I.
Cyclic GMP phosphodiesterase inhibitors. 2. Requirement of
6-substitution of quinazoline derivatives for potent and selective
inhibitory activity. J Med Chem 1994; 37: 2104_11.
123 Takase Y, Saeki T, Fujimoto M, Saito I. Cyclic GMP
phosphodiesterase inhibitors. 1. The discovery of a novel potent inhibitor,
4-((3,4-(methylenedioxy)benzyl)amino)-6,7,8-trimethoxyquinazoline
. J Med Chem 1993; 36: 3765_70.
124 Lee SJ, Konishi Y, Yu DT, Miskowski TA, Riviello CM, Macina
OT, et al. Discovery of potent cyclic GMP phosphodiesterase
inhibitors. 2-Pyridyl- and 2-imidazolylquinazolines possessing
cyclic GMP phosphodiesterase and thromboxane synthesis
inhibitory activities. J Med Chem 1995; 38: 3547_57.
125 Watanabe N, Adachi H, Takase Y, Ozaki H, Matsukura M, Miyazaki
K, et al. 4-(3-Chloro-4-methoxybenzyl) aminophthalazines:
synthesis and inhibitory activity toward phosphodiesterase 5. J
Med Chem 2000; 43: 2523_9.
126 Watanabe N, Kabasawa Y, Takase Y, Matsukura M, Miyazaki K,
Ishihara H, et al. 4-Benzylamino-1-chloro-6-substituted
phthalazines: synthesis and inhibitory activity toward
phosphodiesterase 5. J Med Chem 1998; 41: 3367_572.
127 Daugan A. Tetracyclic derivatives, process of preparation and
use. Patent 1995; WO9519978.
128 Oku T, Sawada K, Kuroda A, Ohne K, Nomoto A, Hosogi N,
et al. Indole derivatives as cGMP-PDE inhibitors. Patent 1996;
WO9632379.
129 Kloner RA, Brown M, Prisant LM, Collins M. Effect of sildenafil
in patients with erectile dysfunction taking antihypertensive
therapy. Am J Hypertens 2001; 14: 70_3.
130 Derry FA, Dinsmore WW, Fraser M, Gardner BP, Glass CA,
Maytom MC, et al. Efficacy and safety of oral sildenafil
(Viagra®) in men with erectile dysfunction caused by spinal cord injury.
Neurology 1998; 51: 1629_33.
131 McMahon CG, Samali R, Johnson H. Efficacy, safety, and
patient acceptance of sildenafil as treatment for erectile
dysfunction. J Urol 2000; 164: 1192_6.
132 Marks LS, Duda C, Dorey FJ. Treatment of erectile dysfunction
with sildenafil. Urology 1999; 53: 19_24.
133 Moreira SG Jr, Brannigan RE, Spitz A, Orejuela FJ, Lipshultz LI,
Kim ED. Side-effect profile of sildenafil citrate (Viagra) in
clinical practice. Urology 2000; 56: 474_6.
134 Jarow JP, Burnett AL, Geringer AM. Clinical efficacy of sildenafil
citrate based on etiology and response to prior treatment. J Urol
1999; 162: 722_5.
135 Morales A, Gingell C, Collins M, Wicker PA, Osterloh IH.
Clinical safety of oral sildenafil citrate (Viagra) in the treatment of
erectile dysfunction. Int J Impot Res 1998; 10: 69_74.
136 Montorsi F, Hellstrom WJ, Valiquette L, Bastuba M, Collins O,
Taylor T, et al. Vardenafil provides reliable efficacy over time in
men with erectile dysfunction. Urology 2004; 64: 1187_95.
137 Hellstrom WJ, Gittelman M, Karlin G, Segerson T, Thibonnier
M, Taylor T, et al. Vardenafil for treatment of men with erectile
dysfunction: efficacy and safety in a randomized, double-blind,
placebo-controlled trial. J Androl 2002; 23: 763_71.
138 Porst H, Young JM, Schmidt AC, Buvat J, International Vardenafil
Study Group. The efficacy and tolerability of vardenafil, a new
oral selective phosphodiesterase type 5 inhibitor in patients with
erectile dysfunction: the first at home clinical trial. Int J Impot
Res 2001; 13: 192_9.
139 Hellstrom WJ, Gittelman M, Karlin G, Segerson T, Thibonnier
M, Taylor T, et al. Sustained efficacy and tolerability of
vardenafil, a highly potent selective phosphodiesterase type 5
inhibitor, in men with erectile dysfunction: results of a randomized,
double-blind, 26-week placebo-controlled pivotal trial. Urology
2003; 61 (Suppl 4A): 8_14.
140 Althof SE. Quality of life and erectile dysfunction. Urology
2002; 59: 803_10.
141 Fugl-Meyer AR, Lodnert G, Branholm IB, Fugl-Meyer KS. On
life satisfaction in male erectile dysfunction. Int J Impot Res
1997; 9: 141_8.
142 Hellstrom WJ, Overstreet JW, Yu A, Shen W, Beasley CM,
Watkins VS. Tadalafil has no effect on spermatogenesis or
reproductive hormones. J Urol 2003; 70: 887_91.
143 Montorsi F, Verheyden B, Junemann KP, Moncado I, Valiquette
L, Denne J, et al. Long-term safety experience with tadalafil. J
Urol 2003; 169: 244.
144 Weeks JL, Zoraghi R, Beasley A, Sekhar KR, Francis SH, Corbin
JD. High biochemical selectivity of tadalafil, sildenafil and
vardenafil for human phosphodiesterase 5A1 (PDE5) over
PDE11A4 suggests the absence of PDE11A4 cross-reaction in
patients. Int J Impot Res 2005; 17: 5_9.
145 Reffelmann T, Kloner RA. Therapeutic potential of
phosphodiesterase 5 inhibition for cardiovascular disease. Circulation 2003;
108: 239_44.
146 Porst H. IC351 (tadalafil, Cialis): update on clinical experience.
Int J Impot Res 2002; 14 (Suppl 1): S57_64.
147 Loughney K, Taylor J, Florio VA. 30,50-cyclic nucleotide
phosphodiesterase 11A: localization in human tissues. Int J Impot
Res 2005; 17: 320_5.
148 Yuasa K, Kanoh Y, Okumura K, Omori K. Genomic
organization of the human phosphodiesterase PDE11A gene:
evolutionary relatedness with other PDEs containing GAF domains. Eur J
Biochem 2001; 268: 168_78.
149 Baxendale RW, Burslem F, Phillips SC. Phosphodiesterase type
11 (PDE11) cellular localization: progress towards defining a
physiological role in testis and/or reproduction. J Urol 2001;
165 (Suppl): Abstract 1395.
150 Ueckert S, Hedlund P, Oelke M, Steif C. Immunohistochemical
presence of phosphodiesterase (PDE)11A in the human prostate
[abstract]. Eur Urol 2004; 3 (Suppl): 18.
151 Padma-Nathan H, Rosen RC, Shobsigh R, Watkins VS, Pullman
B. Cialis (IC351) provides prompt response and extended
responsiveness for the treatment of erectile dysfunction. J Urol
2001; 165 (Suppl): 224.
152 Kloner RA, Mitchell M, Emmick JT. Cardiovascular effects of
tadalafil in patients on common antihypertensive therapies. Am
J Cardiol 2003; 92 (Suppl): 47M_57M.
153 Sikka S, Hellstrom W. The application of pentoxifylline in the
stimulation of sperm motion in men undergoing electroejaculation.
J Androl 1991; 12: 165_70.
154 Tesarik J, Thebault A, Testart J. Effect of pentoxifylline on
sperm movement characteristics in normozoospermic and
asthenozoospermic specimens. Hum Reprod 1992; 7: 1257_63.
155 Tournaye H, Devroey P, Camus M, Van der Linden M, Janssens
R, Van Steirteghem A. Use of pentoxifylline in assisted
reproductive technology. Hum Reprod 1995; 10: 72_9.
156 Schill WB, Pritsch W, Preissler G. Effect of caffeine and
kallikrein on cryo-preserved human spermatozoa. Int J Fertil 1979;
24: 27_32.
157 Schill WB. Caffeine- and kallikrein-induced stimulation of human
sperm motility: a comparative study. Andrologia 1975; 7: 229_36.
158 De Turner E, Aparicio NJ, Turner D, Schwarzstein L. Effect of
two phosphodiesterase inhibitors, cyclic adenosine
3':5'-monophosphate, and a beta-blocking agent on human sperm
motility. Fertil Steril 1978; 29: 328_31.
159 Haesungcharern A, Chulavatnatol M. Stimulation of human
spermatozoal motility by caffeine. Fertil Steril 1973; 24: 662_5.
160 Jaiswal BS, Majumder GC. Cyclic AMP phosphodiesterase: a
regulator of forward motility initiation during epididymal sperm
maturation. Biochem Cell Biol 1996; 74: 669_74.
161 Levin RM, Greenberg SH, Wein AJ. Quantitative analysis of the
effects of caffeine on sperm motility and cyclic adenosine
3',5'-monophosphate (AMP) phosphodiesterase. Fertil Steril 1981;
36: 798_802.
162 Wang C, Chan CW, Yong KK, Yeung K.K. Comparison of the
effectiveness of placebo, clomiphene citrate, mesterolone,
pentoxifylline, and testosterone rebound therapy for the
treatment of idiopathic oligospermia. Fertil Steril 1983; 40: 358_65.
163 Marrama P, Baraghini GF, Carani C, Celani MF, Giovenco P,
Grandi F, et al. Further studies on the effect of pentoxifylline on
sperm count and sperm motility in patients with idiopathic
oligo-asthenozoospermia. Andrologia 1985; 17: 612_6.
164 Shen MR, Chiang PH, Yang RC, Hong CY, Chen SS. Pentoxifylline
stimulates human sperm motility both in
vitro and after oral therapy. Br J Clin Pharmacol 1991; 31: 711_4.
165 Moohan JM, Winston RML, Lindsay KS. The variable effectsof
2-deoxyadenosine on human sperm motility and hyperactivation
in vitro. Hum Reprod 1995; 10: 1098_103.
166 Pang SC, Chan PJ, Lu A. Effects of pentoxifylline on sperm
motility and hyperactivation in normozoospermic and
normokinetic semen. Fertil Steril 1993; 60: 336_43.
167 Fuse H, Sakamoto M, Ohta S, Katayama T. Effect of
pentoxifylline on sperm motion. Arch Androl 1993; 31: 9_15.
168 Tournaye H, Van Steirteghem AC, Devroey P. Pentoxifylline in
idiopathic male-factor infertility: a review of its therapeutic
efficacy after oral administration. Hum Reprod 1994; 9: 996_1000.
169 Yovich JM, Edirisinghe WR, Cummins JM, Yovich JL.
Preliminary results using pentoxifylline in a pronuclear stage tubal
transfer (PROST) program for severe male factor infertility. Fertil
Steril 1988; 50: 179_81.
170 Yovich JM, Edirisinghe WR, Cummins JM, Yovich JL. Influence
of pentoxifylline in severe male factor infertility. Fertil Steril
1990; 53: 715_22.
171 Tasdemir M, Tasdemir I, Kodama H, Tanaka T. Pentoxifylline
enhanced acrosome reaction correlates with fertilization
in vitro. Hum Reprod 1993; 8: 2102_7.
172 Yunes R, Fernández P, Doncel GF, Acosta AA. Cyclic nucleotide
phosphodiesterase inhibition increases tyrosine phosphorylation
and hyper motility in normal and pathological human
spermatozoa. Biocell 2005; 29: 287_93.
173 Stefanovich V. Effect of 3,7-dimethyl-1-(5-oxohexyl)-xanthine
and 1-hexyl-3,7-dimethyl-xanthine on cyclic AMP
phosphodiesterase of the human umbilical cord vessels. Res Commun Chem
Pathol Pharmacol 1973; 5: 655_62.
174 Garbers DL, Kopf GS. The regulation of spermatozoa by calcium
cyclic nucleotides. Adv Cyclic Nucleotide Res 1980; 13: 251_306.
175 Tash JS, Means AR. Cyclic adenosine 3',5' monophosphate,
calcium and protein phosphorylation in flagellar motility. Biol
Reprod 1983; 28: 75_104.
176 Ward A, Clissold SP. Pentoxifylline: a review of its
pharmacodynamic and pharmacokinetic properties, and its therapeutic
efficiency. Drugs 1983; 34: 50_60.
177 Twigg J, Fulton N, Gomez E, Irvine DS, Aitken RJ. Analysis of
the impact of intracellular reactive oxygen species generation
on the structural and functional integrity of human spermatozoa:
Lipid peroxidation, DNA fragmentation and effectiveness of
antioxidants. Hum Reprod 1998; 13: 1429_36.
178 Lopes S, Jurisicova A, Sun JG, Casper RF. Reactive oxygen
species: potential cause forDNAfragmentation in human
spermatozoa. Hum Reprod 1998; 13: 896_900.
179 Kinutani M. Effects of pentoxifylline on sperm motion
characteristics in normozoospermic men defined by a computer-aided
sperm analysis. Hiroshima J Med Sci 1999; 48: 117_21.
180 Kay VJ, Coutts JR, Robertson L. Pentoxifylline stimulates
hyperactivation in human spermatozoa. Hum Reprod 1993; 8:
727_31.
181 Lewis SE, Moohan JM, Thompson W. Effects of pentoxifylline
on human sperm motility in normospermic individuals using
computer-assisted analysis. Fertil Steril 1993; 59: 418_23.
182 Moohan JM, Winston RML, Lindsay KS. Variability of human
sperm response to immediate and prolonged exposure to
pentoxifylline. Hum Reprod 1993; 8: 1696_1700.
183 Tournaye H, Janssens R, Devroey P, Van Steirteghem A. The
influence of pentoxifylline on motility and viability of spermatozoa from
normozoospermic semen samples. Int J Androl 1994; 17: 1_8.
184 Centola GM, Cartie RJ, Cox C. Differential responses of human
sperm to varying concentration of pentoxifylline with
demonstration of toxicity. J Androl 1995; 16: 136_42.
185 Paul M, Sumpter JP, Lindsay KS. Factors affecting pentoxifylline
stimulation of sperm kinematics in suspension. Hum Reprod
1996; 11: 1929_35.
186 Nassar Á, Mahony M, Morshedi M, Lin MH, Srisombut C,
Oehninger S. Modulation of sperm tail protein tyrosine
phosphorylation by pentoxifylline and its correlation with
hyperactivated motility. Fertil Steril 1999; 71: 919_23.
187 Purvis K, Muirhead GJ, Harness JA. The effects of sildenafil
citrate on human sperm function in healthy volunteers. Br J Clin
Pharmacol 2002; 53: 53S_60S.
188 Aversa A, Mazzilli F, Rossi T, Delfino M, Isidori MA, Fabbri A.
Effects of sildenafil (Viagra) administration on seminal
parameters and post-ejaculatory refractory time in normal males.
Hum Reprod 2000; 15: 131_4.
189 Tur-Kaspa I, Segal S, Moffa F, Massobrio M, Meltzer S. Viagra
for temporary erectile dysfunction during treatments with
assisted reproductive technologies: case report. Hum Reprod 1999;
14: 1783_4.
190 du Plessis SS, de Jongh PS, Franken DR. Effect of acute
in vivo sildenafil citrate and in
vitro 8-bromo-cGMP treatments on semen parameters and sperm function. Fertil Steril 2004; 81:
1026_33.
191 Jannini EA, Lombardo F, Salacone P, Gandini L, Lenzi A.
Treatment of sexual dysfunctions secondary to male infertility with
sildenafil citrate. Fertil Steril 2004; 81: 705_7.
192 Lenzi A, Lombardo F, Salacone P, Gandini L, Jannini EA. Stress,
sexual dysfunctions, and male infertility. J Endocrinol Invest
2003; 26 (3 Suppl): 72_6.
193 Yamamoto Y, Sofikitis N, Mio Y, Miyagawa I. Influence of sexual
stimulation on sperm parameters in semen samples collected via
masturbation from normozoospermic men participating in an
assisted reproduction program. Andrologia 2000; 32:131_8.
194 Sofikitis N, Miyagawa I. Endocrinological, biophysical, and
biochemical parameters of semen collected via masturbation versus
sexual intercourse. J Androl 1993; 14: 366_73.
195 Salisbury GW, Vandermark NL. Physiology of Reproduction and
Artificial Insemination of Cattle. San Fransisco: Freeman 1961;
395_6.
196 Sharma OP, Hays RL. Release of an oxytocin substance following
genital stimulation in bulls. J Reprod Fertil 1973; 35: 359_62.
197 Hafs HD, Knisely RC, Desjardens C. Sperm output of dairy bulls
with varying degrees of sexual preparation. J Dairy Sci 1962;
35: 359_62.
198 Kanakas N, Sofikitis N, Kawamura H, Mantzavinos T. Effects
of Hormones on spermatogenesis in men histological diagnosis
of spermatogenic arrest at the primary spermatocytes (PS) stage.
VIIth International Congress of Andrology. June 15_19, 2001,
Montréal, Canada. Abstracts_President's Posters PP-036 J Androl
2001; 22: 192_204.
199 Sofikitis N, Miyagawa I. Secretory dysfunction of the male
accessory genital glands due to prostatic infections and fertility; a
selected review of the literature. Jpn J Fertil Steril 1991; 36: 690_9.
200 Portnoy L. The diagnosis and prognosis of male infertility: a
study of 44 cases with special reference to sperm morphology. J
Urol 1946; 48: 735.
201 Ponchietti R, Raugei A, Lanciotti E, Ademollo B, Galvan P,
Poggini G. Calcium, zinc, magnesium, concentration in seminal
plasma of infertile men with prostatitis. Acta Eur Fertil 1984;
15: 283_5.
202 Fair WR, Couch J, Wehner N. The purification and assay of
prostatic antibacterial factor (PAF). Biochem Med 1973; 8:
329_39.
203 Meares EM Jr. Prostatitis. Med Clin North Am 1991; 75: 405_24.
204 Ali ST, Rakkah NI. Neurophysiological role of sildenafil citrate
(Viagra) on seminal parameters in diabetic males with and
without neuropathy. Pak J Pharm Sci 2007; 20: 36_42.
205 Pomara G, Morelli G, Canale D, Turchi P, Caglieresi C, Moschini
C, et al. Alterations in sperm motility after acute oral
administration of sildenafil or tadalafil in young, infertile men. Fertil
Steril 2007; 88: 860_5.
206 Nomura M, Vacquier VD. Proteins associated with soluble
adenylyl cyclase in sea urchin sperm flagella. Cell Motil
Cytoskeleton 2006; 63: 582_90.
207 Guzick DS, Overstreet JW, Factor-Litvak P, Brazil CK, Nakajima
ST, Coutifaris C, et al; National Cooperative Reproductive
Medicine Network. Sperm morphology, motility, and concentration
in fertile and infertile men. N Engl J Med 2001; 345: 1388_93.
208 Bauer RJ, Rohde G. A single dose of Vardenafil had no acute
effect on sperm motility in healthy males.
27th annual meeting of the American Society of Andrology, April 24_27, 2002, Seattle,
Washington, USA.
209 Grammeniatis E, Kanakas N, Tsounapi P, Baltogiannis D,
Miyagawa I, Sofikitis N. Effects of vardenafil in sperm
parameters and semen biochemistry. 32nd annual meeting of
American Society of Andrology, 21_25 April, Tampa, USA. J
Androl(Suppl). 2007; 28: 60.
210 Burger M, Sikka SC, Bivalacqua TJ, Lamb DJ, Hellstrom WJ.
The effect of sildenafil in human sperm motion and function of
normal and infertile men. Int J Impot Res 2000; 12: 229_34.
211 Olmsted SS, Dubin NH, Cone RA, Moench TR. The rate at
which human sperm are immobilized and killed by mild acidity.
Fertil Steril 2000; 73: 687_93.
212 Su YH, Vacquier VD. Cyclic GMP-specific phosphodiesterase-5
regulates motility of sea urchin spermatozoa. Mol Biol Cell
2006; 17: 114_21.
213 Mostafa T. In vitro sildenafil citrate use as a sperm motility
stimulant. Fertil Steril 2007; 88: 994_6.
214 Lefièvre L, De Lamirande E, Gagnon C. The cyclic
GMP-specific phosphodiesterase inhibitor, sildenafil, stimulates human
sperm motility and capacitation but not acrosome reaction. J
Androl 2000; 21: 929_37.
215 Naro F, Zhang R, Conti M. Developmental regulation of unique
adenosine 3',5'-monophosphate-specific phosphodiesterase variants
during rat spermatogenesis. Endocrinology 1996; 137: 2464_72.
216 Cuadra DL, Chan PJ, Patton WC, Stewart SC, King A. Type 5
phosphodiesterase regulation of human sperm motility. Am J
Obstet Gynecol 2000; 182: 1013_5.
217 Glenn D, McVicar CM, McClure N, Lewis SE. Sildenafil citrate
improves sperm motility but causes a premature acrosome
reaction in vitro. Fertil Steril 2007; 87: 1064_70.
218 Mostafa T. Tadalafil as an in
vitro sperm motility stimulant. Andrologia 2007; 39: 12_5.
219 Ho HC, Granish KA, Suarez SS. Hyperactivated motility of bull
sperm is triggered at the axoneme by
Ca2+ and not cAMP. Dev Biol 2002; 250: 208_17.
220 Carr DW, Fujita A, Stentz CL, Liberty GA, Olson GE, Narumiya
S. Identification of sperm-specific proteins that interact with
A-kinase anchoring proteins in a manner similar to the type II
regulatory subunit of PK-A. J Biol Chem 2001; 276: 17332_8.
221 Burton KA, Treash-Osio B, Muller CH, Dunphy EL, McKnight
GS. Deletion of type IIa regulatory subunit delocalizes protein
kinase A in mouse sperm without affecting motility or fertilization.
J Biol Chem 1999; 274: 24131_6.
222 Wayman C, Phillips S, Lunny C, Webb T, Fawcett L, Baxendale
R, et al. Phosphodiesterase 11 (PDE11) regulation of
spermatozoa physiology. Int J Impot Res 2005; 17: 216_23.
|